Screenshot_2026-07-07-14-45-55-658_com.google.android.apps.docs.jpg

Hi I actually need to u to analyse n give me the topic for my case presentation among these list of disease I am 3rd yr Pharm D student n I need structured analytically topper style unique case topic to be selected high yield n marks scoring infact highest for my final exam case presentation the subject is pharmacotherapeutics

analyse_media

No worries - I can clearly read the image directly. Let me analyze the full syllabus list you've shared.

From the image, I can see your Pharmacotherapeutics-II syllabus covers these topics:

Infectious Diseases - Antibiotics guidelines, Prophylaxis, TB, Meningitis, RTI, Gastroenteritis, Endocarditis, Septicemia, UTI, Malaria, HIV, Fungal infections, Viral infections, Gonorrhoea, Syphilis
Musculoskeletal - Rheumatoid Arthritis, Osteoarthritis, Gout, Spondylitis, SLE
Renal System - Acute Renal Failure, CRF, Renal Dialysis, Drug-induced renal disorders
Oncology - Cancer therapy basics, Breast cancer, Leukemia, Chemo nausea/emesis
Dermatology - Psoriasis, Scabies, Eczema, Impetigo

Now let me give you my full strategic analysis:

🎯 Top Case Topic Recommendation: Septicemia (Sepsis) with Multi-Drug Resistant Organisms

Here is my complete breakdown of why and how to structure it.

Strategic Analysis: Why Sepsis Wins

Scoring Criteria Assessment

Factor	Sepsis	TB	RA	AKI	Leukemia
Pharmacotherapy depth	⭐⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐	⭐⭐⭐
Clinical relevance	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐
Uniqueness/Rarity picked	⭐⭐⭐⭐⭐	⭐⭐	⭐⭐⭐	⭐⭐⭐	⭐⭐⭐⭐
Drug monitoring scope	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐
Marks-scoring potential	⭐⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐

The Ideal Case Title

"A Case of Community-Acquired Septicemia with Suspected MRSA Bacteremia - Pharmacotherapeutic Decision-Making, TDM of Vancomycin, and Sequential Antibiotic De-escalation"

This title alone signals to examiners that you understand:

Empiric vs. targeted therapy
Therapeutic Drug Monitoring (TDM) - pure PharmD territory
Antibiotic stewardship - a hot, current topic

Why NOT the "Common" Choices (Important)

TB - Every student picks this. Examiners are bored of it.
Rheumatoid Arthritis - Good, but drug options are somewhat predictable (DMARDs).
UTI - Too simple for 3rd year PharmD exam.
Breast Cancer - Complex but examiners may want deeper oncology knowledge you may not be tested on.
Malaria - Good but limited pharmacotherapy discussion scope.

Full Structured Case Presentation Framework (Topper Style)

Section 1 - Patient Profile (5 min)

55-year-old male, diabetic, admitted with high-grade fever, chills, hypotension
Source: suspected IV catheter-related infection
Culture: pending at admission (key teaching point - empiric therapy)

Section 2 - Pathophysiology (5 min)

SIRS criteria - heart rate, temperature, WBC, RR
Sepsis vs. severe sepsis vs. septic shock (Sepsis-3 definitions, 2016)
Cytokine cascade: IL-1, IL-6, TNF-alpha - show you understand mechanism

Section 3 - Pharmacotherapy (THE CORE - 15 min)

Step 1: Empiric Therapy

Rationale for broad-spectrum: Piperacillin-tazobactam OR Meropenem
Add Vancomycin if MRSA suspected
"1-hour bundle" from Surviving Sepsis Campaign guidelines

Step 2: TDM of Vancomycin - This is your PharmD-specific differentiator

AUC/MIC-guided dosing (current 2020 ASHP/IDSA/SIDP guideline recommends AUC:MIC ≥ 400-600)
Trough-only monitoring is now outdated - mention this, examiners love it
Renal function adjustment (CrCl calculation - Cockcroft-Gault)
Nephrotoxicity monitoring

Step 3: De-escalation after culture report

If MSSA: switch Vancomycin to Nafcillin/Oxacillin (better outcomes, less nephrotoxicity)
If GNB: narrow to sensitive antibiotic per culture
Duration of therapy discussion

Step 4: Adjunctive therapy

IV fluids: 30 mL/kg crystalloid bolus (Normal Saline vs. Balanced crystalloids)
Vasopressors: Norepinephrine as first-line
Hydrocortisone if refractory septic shock
Blood glucose control - insulin protocol (target 140-180 mg/dL)
DVT prophylaxis - Heparin
Stress ulcer prophylaxis - PPI

Section 4 - Monitoring Parameters (5 min)

Clinical: BP, HR, urine output (>0.5 mL/kg/hr), temp, mental status
Labs: Procalcitonin for antibiotic duration guidance, Lactate clearance, CBC, CRP, LFT, RFT
Drug-specific: Vancomycin AUC monitoring, SCr daily

Section 5 - Patient Counseling (3 min)

Compliance with IV to oral switch
Signs of recurrence
Hygiene, catheter care

Section 6 - Pharmacoeconomics (Bonus marks)

Cost of Meropenem vs. Pip-tazo
TDM reduces overall drug cost by preventing nephrotoxicity and optimizing dosing

Second Best Option (Backup): Infective Endocarditis

If you want something slightly less common but equally high-yield:

Case title: "Pharmacotherapy of Native Valve Infective Endocarditis due to Streptococcus viridans - Duke Criteria, Prolonged Bactericidal Therapy, and Monitoring of Aminoglycosides"

Why it's great:

Duke criteria for diagnosis = clinical pharmacist's role in diagnosis
Gentamicin TDM - another PharmD-specific skill
4-6 week IV therapy = complex case
Surgical vs. medical management decision

Third Option: Drug-Induced Renal Disorders (Nephrotoxicity)

Case title: "Aminoglycoside-Induced Acute Tubular Necrosis in a Post-Surgical Patient - Identification, Management and Prevention Strategies"

Why it stands out:

Directly links pharmacotherapy to iatrogenic harm - perfect PharmD case
Covers 2 syllabus sections at once (Infectious disease + Renal system)
Drug dose adjustment in renal failure - very examinable
Prevention discussion: once-daily dosing, TDM, hydration

Final Recommendation Summary

Rank	Topic	Why
#1	Septicemia + MRSA + Vancomycin TDM	Broadest scope, PharmD-specific TDM angle, current guidelines
#2	Infective Endocarditis	Unique, clinically complex, aminoglycoside TDM
#3	Drug-Induced AKI (Aminoglycosides)	Cross-links two syllabus sections, pharmacist-centered

Go with Sepsis/Septicemia. It lets you demonstrate pathophysiology, rational drug selection, dose individualization (TDM), monitoring, de-escalation (antibiotic stewardship), adjunctive therapy, and patient counseling - all in one case. That is the full spectrum of what your examiners are testing in Pharmacotherapeutics. No other topic on your list gives you that width and depth simultaneously.

Actually it doesn't hve more weightage according to examiner specially sepsis

Asking for Preferences

Reading File

Finding Sources

Now let me give you my definitive answer based on everything - your syllabus, examiner's focus on infectious diseases, and slide-based format.

🏆 Final Recommendation: Tuberculosis (TB)

I know - you might think "everyone picks TB." But hear the strategic reasoning before dismissing it:

Your examiner weights Infectious Diseases the highest. Within that section, TB is the most pharmacotherapy-dense topic on the entire list. Here's why it wins over everything else:

Why TB is the Highest-Scoring Pick for YOUR Exam

1. It covers the MOST examinable pharmacotherapy concepts in one case:

First-line HRZE regimen (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol)
Intensive phase vs. continuation phase - two distinct pharmacotherapy decisions
Drug-induced hepatotoxicity - monitoring, management, rechallenge protocol
Drug interactions - Rifampicin is the strongest CYP450 inducer in clinical practice
DOTS (Directly Observed Therapy) - public health pharmacist role
MDR-TB management (second-line drugs: Bedaquiline, Linezolid, Fluoroquinolones)
Adverse drug reaction monitoring: optic neuritis (Ethambutol), peripheral neuropathy (INH), hyperuricemia (PZA), orange discolouration (Rifampicin)
Pyridoxine (B6) co-supplementation with INH - rational prescribing

2. The "Topper Differentiator" - Make It a COMPLEX TB Case

Don't present simple pulmonary TB. Choose one of these angles that instantly elevates your case:

3 High-Impact Case Title Options (Pick One)

🥇 Option A - TB + HIV Co-infection (Strongest Pick)

Title: "Pharmacotherapy of Pulmonary Tuberculosis in an HIV Co-infected Patient - Drug Interactions, Timing of ART Initiation, and Immune Reconstitution Inflammatory Syndrome (IRIS) Management"

Why this destroys the competition:

Covers TWO infectious disease sections (TB + HIV) simultaneously
ART + ATT interaction is one of the most complex drug interaction scenarios in pharmacotherapy
When to start ART in TB (CD4 <50 = start within 2 weeks, CD4 >50 = start by 8 weeks) - very examinable
IRIS is rare to present but extremely impressive - examiners always ask about it
Rifampicin + Efavirenz interaction (CYP3A4 induction) - substitute with Dolutegravir (current WHO 2023 guideline)
Cotrimoxazole prophylaxis - another pharmacist decision point

🥈 Option B - Drug-Resistant TB (MDR-TB)

Title: "A Case of MDR-TB Failure on First-Line HRZE Regimen - Pharmacotherapeutic Re-evaluation, Second-Line Drug Selection, and Adverse Effect Monitoring"

Why it scores high:

Shows disease progression and treatment failure reasoning - pure pharmacotherapy
Bedaquiline + QTc prolongation monitoring (ECG monitoring, drug interaction with Clofazimine)
WHO 2022 BPaL regimen (Bedaquiline + Pretomanid + Linezolid)
Linezolid: myelosuppression and peripheral neuropathy monitoring
You demonstrate awareness of global current guidelines

🥉 Option C - TB Meningitis

Title: "Pharmacotherapy of Tuberculous Meningitis - CNS Penetration of Anti-TB Drugs, Steroid Adjunct Therapy, and Monitoring in a Critically Ill Patient"

Why it's unique:

Almost no student presents this
Drug CNS penetration becomes the core pharmacotherapy question (Rifampicin > PZA > INH for CSF penetration)
Dexamethasone as adjuvant - mechanism, dose, duration
Raised intracranial pressure management
Longer continuation phase (12 months vs 6 months) - rationale discussion

Slide #	Content	Marks Impact
1	Title + Patient demographics	Sets the tone
2	Chief complaints + History	Clinical setup
3	Investigations - CXR, Sputum AFB, CBNAAT/GeneXpert results	Diagnostic workup
4	Diagnosis + WHO classification	Clinical reasoning
5	Pathophysiology of TB (brief - 1 slide)	Shows depth
6	Treatment goals	Pharmacotherapy thinking
7	Drug therapy - Intensive phase (HRZE doses, weight-based)	Core pharmacotherapy
8	Drug therapy - Continuation phase	Rationale for change
9	Drug interactions table (Rifampicin interactions)	High yield
10	Adverse effect monitoring chart	PharmD-specific
11	Your additional complexity slide (HIV/MDR/Meningitis)	Differentiator
12	Monitoring parameters + Lab values	Structured monitoring
13	Patient counselling points	Clinical pharmacist role
14	Outcome + Discharge plan	Case resolution
15	References (Dipiro, WHO guidelines 2022)	Professionalism

Final Decision Table

Topic	Examiner Weightage	Pharmacotherapy Depth	Uniqueness	Slide-Worthy
TB + HIV	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐
MDR-TB	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐⭐
TB Meningitis	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐
Infective Endocarditis	⭐⭐⭐⭐	⭐⭐⭐⭐⭐	⭐⭐⭐⭐	⭐⭐⭐⭐
Malaria (complicated)	⭐⭐⭐⭐	⭐⭐⭐	⭐⭐⭐	⭐⭐⭐

Go with Option A: TB + HIV Co-infection. It is the highest-ceiling topic in your entire syllabus - it covers two high-yield infectious disease sections, contains the richest drug interaction story in pharmacotherapy, and is rare enough that it will stand out. Examiners who love infectious diseases will have a field day asking you questions - which is exactly what you want when you know the material well, because more viva questions = more marks opportunity.

Can u generate me a case frm scratch to hero kind for the case titled Pharmacotherapy of Native Valve Infective Endocarditis due to Streptococcus viridans - Duke Criteria, Prolonged Bactericidal Therapy, and Monitoring of Aminoglycosides

Finding Sources

Reading File

Finding Sources

Reading File

Here is your complete, topper-level case presentation - built from scratch to hero using Harrison's (2025), Washington Manual, Fuster & Hurst's Heart, and Goldman-Cecil Medicine.

📋 CASE PRESENTATION

Pharmacotherapy of Native Valve Infective Endocarditis due to Streptococcus viridans

Duke Criteria | Prolonged Bactericidal Therapy | Aminoglycoside TDM

SLIDE 1 - PATIENT PROFILE

Parameter	Details
Name	Mr. Rajan K. (fictional)
Age/Sex	42 years / Male
Occupation	Office employee
Ward/IP No.	Medicine Ward, IP: 2024-XXXX
Date of Admission	Day 1
Date of Presentation	Day 28 (Discharge)

SLIDE 2 - CHIEF COMPLAINTS

Fever - low-grade, intermittent, for 3 weeks
Fatigue and malaise - 3 weeks
Joint pain (arthralgias) - bilateral, migratory - 2 weeks
Shortness of breath on exertion - 1 week
Chills and night sweats - 2 weeks

Teaching point for examiners: The insidious onset of 3+ weeks of low-grade fever + arthralgias + fatigue in a patient without obvious infection source = classic Subacute Bacterial Endocarditis (SBE) pattern. Do NOT wait for high fever.

SLIDE 3 - HISTORY

Past Medical History

Rheumatic Heart Disease (diagnosed age 14) - known mitral valve regurgitation
No diabetes, no hypertension, no prior surgeries

History of Presenting Illness

Patient visited a dentist 6 weeks ago for tooth extraction (no antibiotic prophylaxis was given). Three weeks later, developed low-grade fever (37.8-38.2°C), progressive fatigue, arthralgia, and mild breathlessness. Treated empirically at a local clinic with amoxicillin 500 mg TID for 5 days without improvement, then referred to hospital.

Social History

No IV drug use
Non-smoker, occasional alcohol
No recent hospitalizations or IV catheter use

Family History

Non-contributory

SLIDE 4 - PHYSICAL EXAMINATION

System	Findings
General	Pale, febrile (38.4°C), not in distress
Pulse	96/min, regular
BP	110/70 mmHg
RR	20/min
SpO2	96% room air
Cardiovascular	Pansystolic murmur grade III/VI at apex, radiating to axilla (mitral regurgitation)
Eyes	Roth spots on fundoscopy (flame-shaped retinal hemorrhages with white centers)
Hands	Splinter hemorrhages under nails (3-4 fingers), Osler nodes (tender nodules on fingertips)
Feet	Janeway lesions (non-tender erythematous macular lesions on palms and soles)
Abdomen	Mild splenomegaly

Examiner Gold: Roth spots + Osler nodes = immunologic phenomena. Janeway lesions + splinter hemorrhages = vascular/embolic phenomena. Both together = strong clinical indicator of IE.

SLIDE 5 - INVESTIGATIONS

Hematology & Chemistry

Test	Patient Value	Normal Range	Significance
Hemoglobin	9.8 g/dL	13-17 g/dL	Anemia of chronic infection
WBC	12,400/mm³	4,000-11,000	Leukocytosis
ESR	78 mm/hr	<20 mm/hr	Elevated - active inflammation
CRP	68 mg/L	<5 mg/L	Elevated
Rheumatoid Factor	Weakly positive	Negative	Immunologic criterion
Serum Creatinine	0.9 mg/dL	0.7-1.2 mg/dL	Normal baseline (critical for TDM)
BUN	18 mg/dL	7-20 mg/dL	Normal
Urinalysis	Mild hematuria, 2+ proteinuria	Normal	Immune complex glomerulonephritis

Microbiology - THE MOST CRITICAL INVESTIGATION

Step taken: Blood cultures x3 sets drawn from different sites, 30 minutes apart, BEFORE starting antibiotics.

Culture Set	Result
Blood Culture Set 1	Streptococcus viridans (alpha-hemolytic) - GROWTH at 18 hrs
Blood Culture Set 2	Streptococcus viridans - GROWTH at 22 hrs
Blood Culture Set 3	Streptococcus viridans - GROWTH at 24 hrs

Sensitivity Report (MIC):

Antibiotic	MIC	Interpretation
Penicillin G	0.08 µg/mL	Susceptible (MIC ≤ 0.12 µg/mL) - Highly susceptible
Ceftriaxone	0.04 µg/mL	Susceptible
Vancomycin	0.5 µg/mL	Susceptible
Gentamicin	4 µg/mL	Susceptible (synergy candidate)

Echocardiography (TTE first, then TEE)

TTE: Oscillating vegetation (8mm x 6mm) on the posterior leaflet of the mitral valve with moderate mitral regurgitation
TEE (confirmatory): Confirmed vegetation, no perivalvular abscess, no fistula, EF = 58%

SLIDE 6 - DIAGNOSIS USING MODIFIED DUKE CRITERIA

(Washington Manual of Medical Therapeutics / Fuster & Hurst's Heart, 15th Ed.)

Major Criteria (2 required for Definite IE)

Criterion	Present?	Evidence in this patient
1. Positive Blood Cultures - typical organism (S. viridans) from 2 separate cultures	✅ YES	All 3 blood culture sets positive for S. viridans (drawn >12 h apart)
2. Echocardiographic evidence - oscillating vegetation on valve	✅ YES	8mm vegetation on mitral valve posterior leaflet (TEE confirmed)

Minor Criteria

Criterion	Present?	Evidence
Predisposing heart condition	✅ YES	Rheumatic heart disease with mitral regurgitation
Fever ≥38°C	✅ YES	38.4°C on admission
Vascular phenomena	✅ YES	Splinter hemorrhages, Janeway lesions
Immunologic phenomena	✅ YES	Osler nodes, Roth spots, weakly positive RF
Microbiologic evidence	Already major criterion	-

Duke Classification: DEFINITE INFECTIVE ENDOCARDITIS

Criterion: 2 MAJOR criteria satisfied (blood cultures + echocardiographic evidence)

AHA/ESC Guideline Note: "A diagnosis of definite IE is established by evidence of two major criteria." - Fuster & Hurst's Heart, 15th Ed.

SLIDE 7 - PATHOPHYSIOLOGY (Brief - 1 Slide)

Dental Extraction (bacteremia)
         ↓
S. viridans enters bloodstream
         ↓
Damaged mitral valve endothelium (from RHD)
         ↓
Bacteria adhere to fibrin-platelet thrombus on valve
         ↓
Colonization → Vegetation formation (bacteria + fibrin + platelets)
         ↓
         ├── Local effects: Valve destruction → MR worsening → Heart failure
         ├── Embolic effects: Vegetation fragments → brain, kidneys, spleen (infarcts)
         └── Immune effects: Circulating immune complexes → glomerulonephritis, Osler nodes, Roth spots

SLIDE 8 - TREATMENT GOALS

Eradicate the infecting organism completely from the vegetation (bactericidal, not bacteriostatic therapy)
Prevent further valvular destruction
Prevent systemic embolic complications
Manage heart failure if present
Prevent relapse (adequate duration of therapy)
Prevent recurrence (antibiotic prophylaxis for future dental procedures)

PharmD Point: IE requires BACTERICIDAL therapy because vegetation is avascular and bacteria are in metabolically inactive state deep inside fibrin. Bacteriostatic drugs (tetracyclines, macrolides) are INADEQUATE. This is a key distinguishing pharmacotherapy principle.

SLIDE 9 - PHARMACOTHERAPY: EMPIRIC THERAPY (Day 1-3, before culture report)

Clinical situation: Patient is clinically stable (SBE pattern), so empiric therapy started while awaiting culture.

Empiric regimen chosen:

Vancomycin 15 mg/kg IV q12h
(Covers MRSA, Strep, Enterococcus until culture confirms)

Rationale: Patient had prior exposure to amoxicillin (partial treatment) → uncertain if organism is resistant. Vancomycin is broad enough to cover while awaiting susceptibility.

SLIDE 10 - PHARMACOTHERAPY: DEFINITIVE THERAPY (After culture + MIC report)

Organism: Streptococcus viridans | MIC for Penicillin: 0.08 µg/mL (≤ 0.12 µg/mL) = Highly Susceptible

(Source: Washington Manual Table 14-7; Fuster & Hurst Table 33-9)

Chosen Regimen: Penicillin G + Gentamicin (2-week combination followed by Penicillin G alone)

Drug	Dose	Route	Frequency	Duration
Aqueous Crystalline Penicillin G	12-18 million units/day (3 million units q4h)	IV	Every 4 hours	4 weeks total
Gentamicin sulfate	3 mg/kg/day (divided into 3 doses = 1 mg/kg q8h)	IV	Every 8 hours	First 2 weeks only

Weight of patient: 65 kg Gentamicin dose calculation: 3 mg/kg/day = 3 × 65 = 195 mg/day = 65 mg q8h

Why Combination (Penicillin + Gentamicin)?

Synergistic bactericidal effect - Penicillin disrupts cell wall → Gentamicin gains entry into bacterial cell → inhibits 30S ribosome → enhanced bacterial killing
Allows shortening of total therapy to 2-week combination rather than 4-week monotherapy for highly susceptible strains
Only used for first 2 weeks to minimize aminoglycoside toxicity risk

Alternatives (when Penicillin not available or allergic):

Situation	Alternative Regimen
Penicillin allergy (mild/moderate)	Ceftriaxone 2g IV once daily × 4 weeks
True penicillin allergy (anaphylaxis)	Vancomycin 30 mg/kg/day in 2 divided doses × 4 weeks (NO gentamicin needed)
MIC 0.12-0.5 µg/mL (relatively resistant)	Penicillin G 4 million units q4h + Gentamicin × 4-6 weeks
MIC >0.5 µg/mL (fully resistant)	Treat as Enterococcal endocarditis - 6-week regimen

SLIDE 11 - THERAPEUTIC DRUG MONITORING (TDM) - THE PHARMACIST'S ROLE ⭐

A. Gentamicin TDM (CORE PharmD Content)

(Harrison's Principles of Internal Medicine, 22nd Ed., 2025; Goldman-Cecil Medicine)

Why TDM for Gentamicin?

Narrow therapeutic index - toxic and therapeutic doses are close
Two mechanisms of toxicity: Nephrotoxicity (tubular cell injury) and Ototoxicity (cochlear/vestibular damage - IRREVERSIBLE)
Toxicity is concentration-dependent AND time-dependent (trough levels matter most)

Target Serum Levels for Gentamicin in Endocarditis (divided dose regimen):

Parameter	Target Level	Timing of Sample
Peak	3-3.5 µg/mL (not >4 µg/mL)	1 hour AFTER 20-30 min IV infusion
Trough	<1 µg/mL	30 min BEFORE next dose

"Target peak and trough serum concentrations of divided-dose gentamicin 1 h after a 20- to 30-min infusion or IM injection are ~3.5 µg/mL and ≤1 µg/mL, respectively." - Harrison's Principles of Internal Medicine, 22nd Ed.

When to draw levels?

First level: after 3rd or 4th dose (steady state = ~5 half-lives = ~10-15 hrs for gentamicin)
Subsequent levels: every 3-4 days if levels stable, more frequently if renal function changes

Dose adjustment in our patient (Day 5 report):

Sample	Day 5 Result	Target	Interpretation	Action
Gentamicin Peak	4.8 µg/mL	3-3.5 µg/mL	ELEVATED	Reduce dose
Gentamicin Trough	1.4 µg/mL	<1 µg/mL	ELEVATED	Increase interval
SCr	1.1 mg/dL	0.7-1.2 mg/dL	Rising (was 0.9)	Monitor closely

Pharmacist Recommendation (Day 5):

Reduce Gentamicin dose from 65 mg q8h → 55 mg q8h
Recheck peak/trough after next 3 doses
Monitor SCr, BUN daily
Check urine output (oliguria = early nephrotoxicity sign)

Revised levels (Day 8):

Peak: 3.2 µg/mL ✅ | Trough: 0.7 µg/mL ✅ - Within target. Continue.

B. Vancomycin TDM (Empiric phase Days 1-3)

Parameter	Target	Our Patient
Trough level	10-15 µg/mL (Strep infections)	12 µg/mL ✅
AUC/MIC (if AUC-guided)	400-600 mg·h/L	Calculated: 480 ✅

Once culture confirmed Strep viridans with MIC ≤ 0.12 µg/mL → Vancomycin stopped, switched to Penicillin G (Day 3).

SLIDE 12 - MONITORING PARAMETERS (Full Chart)

Clinical Monitoring

Parameter	Frequency	Target/Normal
Temperature	Every 6-8 hours	Afebrile within 5-7 days of therapy
Heart rate, BP	Daily	Stable hemodynamics
Heart murmur character	Daily auscultation	No new murmur / no worsening
Urine output	Daily	>0.5 mL/kg/hr
Signs of embolism (new neuro symptoms, flank pain, vision changes)	Each assessment	Absence
Signs of heart failure (JVP, pedal edema, crepitations)	Daily	Absence

Laboratory Monitoring

Test	Frequency	Reason
Blood cultures (repeat)	At 48-72 hrs of therapy	Confirm clearance of bacteremia
Serum Creatinine, BUN	Daily (Gentamicin phase)	Nephrotoxicity detection
Urine analysis	Every 3 days	Early tubular injury (casts)
CBC	Twice weekly	Rule out drug-induced cytopenias
CRP, ESR	Weekly	Trend of inflammation
Gentamicin Peak + Trough	After 3rd dose, then every 3-4 days	TDM (see Slide 11)
Echocardiography (repeat TTE)	Week 2-3 of therapy	Assess vegetation resolution

Ototoxicity Monitoring (Gentamicin-specific)

What to ask/test	Frequency
Ask: any new hearing difficulty, ringing (tinnitus), dizziness	Daily
Formal audiometry	If symptomatic
Baseline audiometry	At admission (before starting Gentamicin)

PharmD Point: Ototoxicity from aminoglycosides is irreversible because it destroys cochlear hair cells permanently. Risk factors: cumulative dose, prior aminoglycoside exposure, concurrent loop diuretics, baseline renal impairment. This is WHY we limit gentamicin to only 2 weeks in IE.

SLIDE 13 - DISEASE COURSE / PATIENT PROGRESS

Day	Event	Pharmacotherapy Action
Day 1	Admission, blood cultures drawn, empiric Vancomycin started	Vancomycin 15 mg/kg IV q12h
Day 3	Blood culture: S. viridans MIC 0.08 µg/mL	Switch to Penicillin G 3 MU q4h + Gentamicin 65 mg q8h
Day 5	Gentamicin peak elevated (4.8), trough elevated (1.4)	Dose reduced to 55 mg q8h
Day 7	Fever resolved, patient feels better	Continue therapy, monitor
Day 8	Gentamicin levels within target	Continue revised dose
Day 14	End of Gentamicin (2 weeks complete)	Stop Gentamicin, continue Penicillin G alone
Day 15	Repeat blood cultures: NEGATIVE	Treatment working
Day 21	Repeat TTE: Vegetation reduced in size (4mm), MR same	Continue Penicillin G
Day 28	4-week Penicillin G complete, patient stable	Discharge

SLIDE 14 - COMPLICATIONS ENCOUNTERED

1. Possible Early Nephrotoxicity (Day 5)

SCr rose from 0.9 → 1.1 mg/dL
Managed by dose reduction of Gentamicin
SCr returned to 0.9 mg/dL by Day 10 after dose adjustment

2. Immune Complex Glomerulonephritis

Hematuria + proteinuria on admission
Managed: Resolved with antibiotic treatment (no steroids needed)
Repeat urinalysis Day 21: protein trace only

3. Embolic Splenic Infarct (Day 6 - incidental finding on CT)

Patient complained of left upper quadrant pain Day 6
CT abdomen: small splenic infarct
Management: Analgesics, NO anticoagulation (risk of hemorrhagic conversion of embolic infarct)
Resolved conservatively

Examiner Tip: IE + embolism → Do NOT anticoagulate unless there is a pre-existing indication (e.g., mechanical valve). Adding anticoagulation increases risk of hemorrhagic stroke. This is a common viva trap.

SLIDE 15 - ANTIBIOTIC PROPHYLAXIS (Prevention - PharmD Role)

(AHA 2007 / ESC 2015 Guidelines)

Before ANY future dental procedure:

Amoxicillin 2g orally, 30-60 minutes before procedure
If penicillin allergy: Clindamycin 600 mg OR Azithromycin 500 mg orally before procedure

Who needs prophylaxis?

Prosthetic heart valves
Prior history of IE ✅ (our patient now qualifies after this episode)
Unrepaired cyanotic congenital heart disease
Cardiac transplant with valvulopathy

SLIDE 16 - PATIENT COUNSELLING

Point	What to Tell Patient
Regarding IV therapy	Explain why 4 weeks of IV antibiotics are needed - bacteria deep in vegetation require prolonged bactericidal exposure
Compliance	Missing even 1 dose can lead to treatment failure and relapse with drug-resistant organism
Signs of toxicity	Report immediately: decreased hearing, ringing in ears, dizziness (Gentamicin ototoxicity), decreased urine output (nephrotoxicity)
Dental hygiene	Excellent oral hygiene reduces bacteremia risk. Regular dental checkups
Prophylaxis	Show antibiotic prophylaxis card; carry it to every dental/surgical visit for LIFE
Follow-up	Cardiology follow-up for mitral valve repair/replacement evaluation (RHD + IE = valve damage likely to progress)
Activity	Avoid strenuous activity until vegetation fully resolved (embolism risk)
Red flags	Return immediately if: fever recurs, new neurological symptoms (stroke), chest pain, severe breathlessness

SLIDE 17 - OUTCOME & DISCHARGE SUMMARY

Parameter	At Admission	At Discharge (Day 28)
Temperature	38.4°C	36.8°C (Afebrile for 14 days)
Blood Culture	Positive - S. viridans	Negative x2
Hemoglobin	9.8 g/dL	11.2 g/dL
CRP	68 mg/L	8 mg/L
Vegetation Size	8mm x 6mm	4mm (TEE)
Mitral Regurgitation	Moderate	Moderate (unchanged - surgical review advised)
Serum Creatinine	0.9 mg/dL	0.9 mg/dL
Hearing	Intact	Intact ✅

Discharge Medications:

No oral antibiotics needed (IV course completed)
Furosemide 20 mg OD (for mild residual MR-related fluid retention)
Lisinopril 2.5 mg OD (for MR - afterload reduction)
Antibiotic prophylaxis card issued

Referral: Cardiology clinic in 2 weeks for valve repair/replacement decision

SLIDE 18 - REFERENCES

Harrison's Principles of Internal Medicine, 22nd Edition (2025), McGraw-Hill - Chapter 63
Fuster & Hurst's The Heart, 15th Edition - Chapter 33 (Tables 33-4, 33-9)
Washington Manual of Medical Therapeutics - Chapter 14 (Tables 14-5, 14-6, 14-7)
Goldman-Cecil Medicine International Edition - Chapter 61
Baddour LM et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. AHA Scientific Statement. Circulation. 2015;132(15):1435-1486
Habib G et al. ESC Guidelines for Management of Infective Endocarditis. Eur Heart J. 2015;36(44):3075-3128
Dipiro JT et al. Pharmacotherapy: A Pathophysiologic Approach, 11th Edition - Chapter 104

EXAMINER VIVA PREPARATION - Expected Questions & Answers

Q1: Why are bacteriostatic antibiotics not used in IE? A: Vegetations are avascular fibrin-platelet matrices with bacteria in metabolically low-activity state and high bacterial density. Bacteriostatic agents only suppress growth - they cannot kill organisms in this protected environment. Only bactericidal agents achieve the sustained killing needed.

Q2: Why is Gentamicin limited to only 2 weeks? A: Aminoglycosides cause irreversible cochlear hair cell destruction (ototoxicity) and dose-dependent renal tubular injury (nephrotoxicity). Synergistic benefit is achieved in the first 2 weeks; continuing beyond this increases toxicity without adding clinical benefit for highly susceptible strains.

Q3: What is the difference between TTE and TEE? A: TTE (transthoracic) has sensitivity 50-60% - used first in all patients. TEE (transesophageal) has sensitivity 90% - used when TTE is negative but suspicion remains high, for prosthetic valves, or when complications (abscess) are suspected.

Q4: Why wasn't anticoagulation given for the splenic embolus? A: Anticoagulation in IE with embolic infarcts risks hemorrhagic transformation of the infarct, particularly cerebral. Unless there is a pre-existing firm indication (mechanical valve, AF), anticoagulation is contraindicated. This principle is supported by AHA 2015 guidelines.

Q5: What is the pharmacist's specific role in this case? A: (i) Recommending appropriate empiric regimen, (ii) Dose calculation for Gentamicin using ideal body weight, (iii) TDM monitoring - timing of peak and trough sampling, interpreting levels, dose adjustment, (iv) Nephrotoxicity/ototoxicity surveillance, (v) Antibiotic prophylaxis counselling, (vi) Patient education on compliance.

Sources: Harrison's Principles of Internal Medicine 22E (2025) | Fuster & Hurst's The Heart 15E | Washington Manual of Medical Therapeutics | Goldman-Cecil Medicine | AHA 2015 Scientific Statement

This is a complete "scratch to hero" case - every finding connects logically to the next, the pharmacotherapy evolves as culture data comes in, a real complication is handled, and the PharmD-specific contributions (TDM, dose adjustment, counselling, prophylaxis) are woven throughout. Present it confidently.

I need the case duration of 5 days with atleast 5 drugs to be added in this case coz drugs r here n there slightly confusing for me can u compile

Here is your clean, compiled 5-day case with all drugs clearly organized in one place.

📋 COMPILED CASE PRESENTATION

Native Valve Infective Endocarditis - Streptococcus viridans

5-Day Hospital Stay | 5 Key Drugs | Clean & Exam-Ready

PATIENT SNAPSHOT


Name	Mr. Rajan K., 42 yrs, Male
Admission	Day 1
Discharge	Day 5 (discharged on oral step-down / OPAT plan)
Diagnosis	Native Valve Infective Endocarditis - Mitral Valve
Causative Organism	Streptococcus viridans (MIC Penicillin = 0.08 µg/mL)
Background	Rheumatic Heart Disease, recent dental extraction (6 weeks ago)

CHIEF COMPLAINTS

Fever (low-grade, intermittent) - 3 weeks
Fatigue, malaise, night sweats - 3 weeks
Migratory joint pain (arthralgias) - 2 weeks
Mild breathlessness on exertion - 1 week

CLINICAL SIGNS (on Examination)

Sign	Finding	Type
Murmur	Pansystolic grade III/VI at apex	Local cardiac
Splinter hemorrhages	Under nails, 3 fingers	Vascular phenomenon
Janeway lesions	Palms and soles, non-tender	Vascular phenomenon
Osler nodes	Tender nodules - fingertips	Immunologic phenomenon
Roth spots	Fundoscopy - flame hemorrhages	Immunologic phenomenon
Splenomegaly	Mild, palpable	Chronic bacteremia
Temperature	38.4°C	Minor Duke criterion

INVESTIGATIONS SUMMARY

Test	Value	Significance
Hb	9.8 g/dL	Anemia of infection
WBC	12,400/mm³	Leukocytosis
CRP	68 mg/L	Active inflammation
ESR	78 mm/hr	Elevated
Rheumatoid Factor	Weakly positive	Immunologic criterion
S. Creatinine	0.9 mg/dL	Baseline - critical for TDM
Urinalysis	Hematuria + 2+ protein	Immune glomerulonephritis
Blood Culture x3	S. viridans (all 3 positive)	Major Duke criterion
Penicillin MIC	0.08 µg/mL (≤0.12)	Highly susceptible
TTE/TEE	8mm vegetation, mitral posterior leaflet, No abscess, EF 58%	Major Duke criterion

DUKE CRITERIA - DEFINITE IE ✅

Criterion	Evidence
MAJOR 1 - Positive blood cultures (typical organism)	S. viridans in 3/3 cultures drawn >12 hrs apart
MAJOR 2 - Echocardiographic evidence of vegetation	8mm oscillating mass on mitral valve (TEE)
MINOR 1 - Predisposing heart condition	Rheumatic heart disease
MINOR 2 - Fever ≥38°C	38.4°C
MINOR 3 - Vascular phenomena	Splinter hemorrhages, Janeway lesions
MINOR 4 - Immunologic phenomena	Osler nodes, Roth spots, +RF

Classification: DEFINITE IE = 2 MAJOR criteria met

💊 DRUG CHART - ALL 5 DRUGS IN ONE PLACE

DRUG 1 - VANCOMYCIN (Empiric, Days 1-2)

Parameter	Details
Indication	Empiric therapy before culture report (covers MRSA, Strep, Enterococcus)
Dose	15 mg/kg IV q12h = 975 mg IV q12h (patient wt: 65 kg)
Route	IV infusion over 60 minutes (slow - to avoid Red Man Syndrome)
Duration	Days 1-2 only (stopped once culture confirmed Strep viridans susceptible to Penicillin)
Mechanism	Inhibits cell wall synthesis by binding D-Ala-D-Ala terminal of peptidoglycan precursor
TDM Target	Trough: 10-15 µg/mL (Streptococcal infection)
Day 2 Trough	12 µg/mL ✅ Within range
Why stopped Day 3	Culture confirmed susceptibility to Penicillin G → de-escalate (Antibiotic stewardship)
ADR to monitor	Red Man Syndrome (rapid infusion), Nephrotoxicity, Ototoxicity

DRUG 2 - PENICILLIN G (Aqueous Crystalline) (Definitive, Days 3-5+)

Parameter	Details
Indication	Definitive therapy for S. viridans NVE (MIC ≤ 0.12 µg/mL = highly susceptible)
Dose	3 million units IV q4h (= 18 million units/day total)
Route	IV continuous or divided doses q4h
Duration	Started Day 3, planned 4 weeks total (continued as OPAT after discharge on Day 5)
Mechanism	Beta-lactam - irreversibly binds Penicillin Binding Proteins (PBPs) → inhibits transpeptidation → cell wall lysis → bactericidal
Why Penicillin G over Amoxicillin	Higher bactericidal potency for S. viridans; parenteral route ensures reliable plasma levels
ADR to monitor	Hypersensitivity (ask allergy Hx), Hypokalemia (large doses of Na/K penicillin salts), Neurotoxicity at very high doses
Drug Interaction	Probenecid increases Penicillin levels (blocks renal tubular secretion)

DRUG 3 - GENTAMICIN (Synergistic, Days 3-5)

Parameter	Details
Indication	Synergistic combination with Penicillin G to enhance bactericidal killing of S. viridans
Dose	3 mg/kg/day = 65 kg × 3 = 195 mg/day ÷ 3 = 65 mg IV q8h
Route	IV over 30 minutes
Duration	First 2 weeks only (Days 3-5 shown here; total planned 14 days then stop)
Mechanism	Aminoglycoside - binds 30S ribosomal subunit → misreading of mRNA → bactericidal (concentration-dependent killing)
Synergy Mechanism	Penicillin disrupts cell wall → Gentamicin entry into cell greatly enhanced → synergistic kill
TDM - PEAK target	3.0 - 3.5 µg/mL (1 hour after 30 min IV infusion)
TDM - TROUGH target	<1 µg/mL (30 min before next dose)
Day 5 TDM Result	Peak: 4.8 µg/mL ❌ (HIGH) \| Trough: 1.4 µg/mL ❌ (HIGH)
Pharmacist Action Day 5	Reduce dose → 55 mg q8h; increase monitoring frequency
ADR - Nephrotoxicity	Tubular cell injury → rising SCr, oliguria; reversible if caught early
ADR - Ototoxicity	Cochlear hair cell destruction → hearing loss, tinnitus; IRREVERSIBLE
Risk factors for toxicity	High trough levels, prolonged therapy, concurrent NSAIDs/diuretics, pre-existing renal impairment

DRUG 4 - FUROSEMIDE (Symptomatic, Days 3-5)

Parameter	Details
Indication	Mild fluid overload / pulmonary congestion secondary to mitral regurgitation (worsened by IE)
Dose	20 mg IV once daily (Days 3-5), then 20 mg oral OD at discharge
Route	IV initially, then oral
Mechanism	Loop diuretic - inhibits Na⁺/K⁺/2Cl⁻ cotransporter in thick ascending loop of Henle → natriuresis, diuresis → reduces preload → relieves pulmonary congestion
Monitoring	Urine output (target >0.5 mL/kg/hr), Serum K⁺ (hypokalemia risk), BP (hypotension), SCr
Day 3 finding	Bilateral fine crepitations at lung bases, SpO2 dropped to 93% → Furosemide added
Day 5 finding	SpO2 back to 97%, crepitations cleared ✅
Important Interaction	Furosemide + Gentamicin = additive ototoxicity risk - monitor hearing closely
ADR	Hypokalemia (supplement with KCl if K+ <3.5), hyponatremia, dehydration

DRUG 5 - PARACETAMOL (Acetaminophen) (Symptomatic, Days 1-5)

Parameter	Details
Indication	Fever (38.4°C), arthralgias, general pain relief
Dose	500 mg - 1g oral/IV q6-8h PRN (max 4g/day)
Route	Oral (IV if oral not tolerated)
Duration	As needed, Days 1-5
Mechanism	Central inhibition of prostaglandin synthesis (COX inhibition in CNS) + activation of descending serotonergic pathways → antipyretic + analgesic
Why NOT NSAIDs (Ibuprofen)?	NSAIDs are avoided in IE - they impair platelet function (risk of hemorrhage from embolic sites), are nephrotoxic (additive with Gentamicin), and may mask fever (clinical monitoring parameter)
Monitoring	LFT if prolonged use; avoid in hepatic impairment
Day 2 outcome	Fever reduced to 37.6°C with paracetamol ✅

📅 5-DAY CLINICAL TIMELINE - EVERYTHING IN ONE TABLE

	Day 1	Day 2	Day 3	Day 4	Day 5
Clinical Status	Febrile 38.4°C, Murmur, Splinter hemorrhages	Fever 38.1°C, SpO2 94%, crepitations bilateral	Afebrile 37.4°C, Crepitations mild	Afebrile, feeling better	Stable, afebrile, SpO2 97%
Culture Report	Sent (pending)	S. viridans isolated	MIC confirmed = 0.08	Sensitivity confirmed	All 3 cultures confirmed
DRUG 1 - Vancomycin	975 mg IV q12h ✅ START	975 mg IV q12h (Trough: 12 ✅)	STOPPED (de-escalate)	-	-
DRUG 2 - Penicillin G	-	-	3 MU q4h IV ✅ START	3 MU q4h IV	3 MU q4h IV (continue OPAT)
DRUG 3 - Gentamicin	-	-	65 mg q8h IV ✅ START	65 mg q8h IV	Dose reduced to 55 mg q8h (TDM: Peak 4.8❌, Trough 1.4❌)
DRUG 4 - Furosemide	-	-	20 mg IV OD ✅ START	20 mg IV OD	20 mg oral OD (for discharge)
DRUG 5 - Paracetamol	500 mg q6h PRN ✅	500 mg q6h PRN	500 mg q8h PRN	PRN (used once)	Stopped (afebrile)
Key Action	Admit, cultures x3, Echo ordered, Empiric Vancomycin	TEE confirms vegetation, Furosemide considered	Culture confirmed → De-escalate to Pen G + Gentamicin, Add Furosemide	Monitor, TDM scheduled	TDM done, Gentamicin dose adjusted, Discharge plan
Pharmacist Role	Empiric regimen recommendation, Vancomycin TDM plan	Vancomycin trough check (12 ✅)	Dose calculation for Pen G + Gentamicin	Counselling begun	TDM interpretation, dose adjustment, discharge counselling

📊 DRUG INTERACTION TABLE

Drug Pair	Interaction	Clinical Significance	Management
Gentamicin + Furosemide	Additive ototoxicity	HIGH - both damage cochlear cells	Use lowest effective Furosemide dose; monitor hearing
Gentamicin + Vancomycin (overlap Day 1-2)	Additive nephrotoxicity	MODERATE	Monitor SCr daily, Vancomycin stopped Day 3
Penicillin G + Probenecid	Probenecid blocks renal secretion → ↑ Penicillin levels	LOW (beneficial if used intentionally)	Not co-prescribed here
Furosemide + Penicillin G	Furosemide can → hypokalemia → may affect drug disposition	LOW	Monitor electrolytes

🔬 TDM SUMMARY CARD

Drug	Target Peak	Target Trough	Day 5 Result	Action Taken
Vancomycin	-	10-15 µg/mL	12 µg/mL ✅	Maintained (then stopped)
Gentamicin	3.0-3.5 µg/mL	<1 µg/mL	Peak 4.8 ❌ Trough 1.4 ❌	Dose reduced 65→55 mg q8h

📤 DISCHARGE SUMMARY (End of Day 5)

Parameter	Status
Temperature	36.8°C - Afebrile for 36 hrs
Blood Pressure	108/70 mmHg
SpO2	97% room air
Blood Culture (repeat Day 5)	Pending - expected negative
Creatinine	0.9 mg/dL (baseline unchanged)
Hearing	Intact

Discharge Medications:

Penicillin G 3 MU IV q4h - continue as OPAT (Outpatient Parenteral Antibiotic Therapy) for remaining 3 weeks (total 4-week course)
Furosemide 20 mg oral OD
Lisinopril 2.5 mg oral OD (afterload reduction for mitral regurgitation)
Antibiotic prophylaxis card issued (Amoxicillin 2g oral before any future dental procedure)

Follow-up: Cardiology in 2 weeks for mitral valve repair/replacement decision

QUICK REVISION - 5 DRUGS AT A GLANCE

#	Drug	Days Used	Why Used	Key Monitoring
1	Vancomycin	Day 1-2	Empiric broad cover (pre-culture)	Trough 10-15 µg/mL
2	Penicillin G	Day 3-5+	Definitive therapy (S. viridans MIC 0.08)	Allergy Hx, Hypokalemia
3	Gentamicin	Day 3-5+	Synergy with Penicillin G (2-week course)	Peak 3-3.5, Trough <1 µg/mL
4	Furosemide	Day 3-5	Fluid overload from MR (pulmonary congestion)	K+, SCr, urine output
5	Paracetamol	Day 1-5 PRN	Fever + arthralgias (NSAIDs contraindicated)	LFT, max 4g/day

Everything is now in one clean, logical flow. The 5-day timeline shows each drug entering and exiting the case with a clear clinical reason, and the TDM adjustment on Day 5 gives you your PharmD-specific high-scoring moment. Print or paste the Day-wise table and the 5-drug summary card onto separate slides and that will be your backbone for the entire presentation.

Wt is the difference between these last 2 responses

Great question. Here is the clear difference:

Response 2 (Original - "Scratch to Hero") vs Response 3 (Compiled - "5-Day Clean")

Feature	Response 2 (Original)	Response 3 (Compiled/Latest)
Case Duration	28 days (full 4-week IE treatment)	5 days (hospital stay only, rest as OPAT)
Number of Drugs	~3-4 drugs mentioned scattered across slides	Exactly 5 drugs, each with full dedicated drug card
Drug Presentation	Drugs mentioned within slides here and there - easy to lose track	All 5 drugs compiled in one place - each has its own table
Timeline	Day-by-day was not a structured table	Single 5-day master table - all drugs, all events, all actions in one row-by-row view
Drug Interaction Table	Mentioned briefly	Dedicated table - 4 drug pairs with clinical significance
TDM	Explained in detail across multiple paragraphs	Condensed TDM summary card - one quick-reference table
Discharge	Day 28 discharge	Day 5 discharge with OPAT plan
Slide Count	18 slides	Fewer, denser, more exam-ready slides
Complexity	Richer narrative, more complications (splenic embolus, nephrotoxicity chapter etc.)	Focused and streamlined - easier to present in limited time
"Drugs here and there" problem	YES - drug info spread across slides 9, 10, 11, 12	SOLVED - one dedicated drug section, one summary table at the end

Which to Use and How

The best approach = combine both:

Use Response 2's pathophysiology, Duke criteria, clinical signs, viva Q&A sections
Use Response 3's 5-day timeline table, 5-drug cards, TDM summary card, drug interaction table as your core slides

Response 2 is your depth and knowledge base. Response 3 is your presentation skeleton. Together they make a complete, topper-level case.

Create a combined PowerPoint deck merging both responses into one cohesive presentation

Reading File

Running Command

mkdir -p /home/daytona/workspace/ie-case-presentation

Writing File

~/ie-case-presentation/build.js

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE";
pres.title = "Pharmacotherapy of Native Valve Infective Endocarditis";
pres.author = "PharmD Case Presentation";

// ── PALETTE ──────────────────────────────────────────────────────────────────
const C = {
  navy:    "0D2137",   // dominant dark
  teal:    "0A7EA4",   // primary accent
  ltTeal:  "E6F4F9",   // light teal bg panels
  gold:    "E8A020",   // highlight / warning
  green:   "1A7A4A",   // positive/OK
  red:     "C0392B",   // alert / high
  white:   "FFFFFF",
  offwhite:"F5F8FA",
  slate:   "4A5568",
  ltGray:  "DDE3EA",
  midGray: "8A9BB0",
};

// ── HELPERS ──────────────────────────────────────────────────────────────────
function addSlideHeader(slide, title, subtitle) {
  // dark bar top
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:13.3, h:1.1, fill:{color:C.navy}, line:{color:C.navy} });
  // teal accent left stripe
  slide.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.22, h:1.1, fill:{color:C.teal}, line:{color:C.teal} });
  slide.addText(title, { x:0.38, y:0.12, w:10, h:0.55, fontSize:20, bold:true, color:C.white, fontFace:"Calibri", margin:0 });
  if (subtitle) slide.addText(subtitle, { x:0.38, y:0.68, w:10, h:0.35, fontSize:11, color:"A8C8DC", fontFace:"Calibri", margin:0, italic:true });
  // slide bg
  slide.background = { color: C.offwhite };
}

function sectionLabel(slide, text, x, y, w) {
  slide.addShape(pres.shapes.RECTANGLE, { x, y, w, h:0.32, fill:{color:C.teal}, line:{color:C.teal}, rectRadius:0 });
  slide.addText(text, { x, y, w, h:0.32, fontSize:10, bold:true, color:C.white, align:"center", valign:"middle", fontFace:"Calibri", margin:0 });
}

function card(slide, x, y, w, h, fillColor) {
  slide.addShape(pres.shapes.RECTANGLE, { x, y, w, h,
    fill:{color: fillColor || C.white},
    line:{color:C.ltGray, pt:1},
    shadow:{type:"outer", color:"000000", blur:5, offset:2, angle:135, opacity:0.08}
  });
}

function tableStyle(rows, colW, opts) {
  return {
    x: opts.x, y: opts.y, w: opts.w, h: opts.h,
    colW: colW,
    border: { pt:0.5, color: C.ltGray },
    fontFace: "Calibri",
    fontSize: opts.fontSize || 10,
    rows: rows,
  };
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 1 – TITLE
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  sl.background = { color: C.navy };

  // gradient-feel: dark top + lighter panel
  sl.addShape(pres.shapes.RECTANGLE, { x:0, y:3.5, w:13.3, h:4, fill:{color:"081828"}, line:{color:"081828"} });
  // teal stripe
  sl.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.35, h:7.5, fill:{color:C.teal}, line:{color:C.teal} });
  sl.addShape(pres.shapes.RECTANGLE, { x:0.35, y:3.38, w:13, h:0.06, fill:{color:C.gold}, line:{color:C.gold} });

  sl.addText("CASE PRESENTATION", { x:0.6, y:0.5, w:12, h:0.55, fontSize:13, bold:true, color:C.gold, charSpacing:5, fontFace:"Calibri" });
  sl.addText("Pharmacotherapy of", { x:0.6, y:1.2, w:12, h:0.7, fontSize:26, color:"B8D8E8", fontFace:"Calibri" });
  sl.addText("Native Valve Infective Endocarditis", { x:0.6, y:1.85, w:12, h:0.85, fontSize:32, bold:true, color:C.white, fontFace:"Calibri" });
  sl.addText("due to Streptococcus viridans", { x:0.6, y:2.65, w:12, h:0.65, fontSize:22, color:"7EC8E3", fontFace:"Calibri", italic:true });

  sl.addText([
    { text: "Duke Criteria  |  Prolonged Bactericidal Therapy  |  Aminoglycoside TDM", options:{} }
  ], { x:0.6, y:4.0, w:12, h:0.5, fontSize:13, color:C.gold, fontFace:"Calibri", align:"left" });

  sl.addText("Pharmacotherapeutics – II  |  3rd Year PharmD Case Presentation", { x:0.6, y:5.0, w:10, h:0.4, fontSize:11, color:C.midGray, fontFace:"Calibri" });
  sl.addText("Subject: Pharmacotherapeutics  |  Reference: Harrison's 22E · Fuster & Hurst 15E · Washington Manual", {
    x:0.6, y:5.55, w:12, h:0.35, fontSize:9, color:"506070", fontFace:"Calibri"
  });

  // heart icon placeholder text
  sl.addShape(pres.shapes.RECTANGLE, { x:10.5, y:1.0, w:2.4, h:2.4, fill:{color:"112233"}, line:{color:C.teal, pt:1.5} });
  sl.addText("♥", { x:10.5, y:1.3, w:2.4, h:1.8, fontSize:64, color:C.red, align:"center", fontFace:"Calibri" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 2 – PATIENT PROFILE & CHIEF COMPLAINTS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Patient Profile & Chief Complaints", "Slide 2 of 18");

  // LEFT CARD – Patient Details
  card(sl, 0.3, 1.25, 5.8, 4.0);
  sectionLabel(sl, "PATIENT DETAILS", 0.3, 1.25, 5.8);

  const pRows = [
    [{ text:"Parameter", options:{bold:true, color:C.white, fill:{color:C.teal}} }, { text:"Details", options:{bold:true, color:C.white, fill:{color:C.teal}} }],
    ["Name", "Mr. Rajan K. (42 yrs / Male)"],
    ["Occupation", "Office Employee"],
    ["Ward", "Medicine Ward, IP: 2024-XXXX"],
    ["Admission", "Day 1"],
    ["Discharge", "Day 5 (OPAT continuation)"],
    ["Background", "Rheumatic Heart Disease"],
    ["Trigger", "Dental extraction 6 weeks ago (no prophylaxis)"],
  ];
  sl.addTable(pRows, { x:0.3, y:1.6, w:5.8, h:3.6, colW:[2.2,3.6], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri",
    autoPage:false,
    rowH: 0.42
  });

  // RIGHT CARD – Chief Complaints
  card(sl, 6.5, 1.25, 6.5, 4.0);
  sectionLabel(sl, "CHIEF COMPLAINTS", 6.5, 1.25, 6.5);

  const complaints = [
    { text:"🌡 Fever (low-grade, intermittent)", options:{bullet:false, breakLine:true} },
    { text:"   Duration: 3 weeks", options:{bullet:false, color:C.midGray, breakLine:true, fontSize:9} },
    { text:"😴 Fatigue, malaise, night sweats", options:{bullet:false, breakLine:true} },
    { text:"   Duration: 3 weeks", options:{bullet:false, color:C.midGray, breakLine:true, fontSize:9} },
    { text:"🦴 Migratory joint pain (arthralgias)", options:{bullet:false, breakLine:true} },
    { text:"   Duration: 2 weeks", options:{bullet:false, color:C.midGray, breakLine:true, fontSize:9} },
    { text:"🫁 Breathlessness on exertion", options:{bullet:false, breakLine:true} },
    { text:"   Duration: 1 week", options:{bullet:false, color:C.midGray, breakLine:true, fontSize:9} },
    { text:"❄ Chills and rigors", options:{bullet:false, breakLine:true} },
    { text:"   Duration: 2 weeks", options:{bullet:false, color:C.midGray, breakLine:false, fontSize:9} },
  ];
  sl.addText(complaints, { x:6.6, y:1.65, w:6.2, h:3.5, fontSize:11, fontFace:"Calibri", color:C.navy, valign:"top" });

  // Teaching point box at bottom
  card(sl, 0.3, 5.4, 12.7, 0.9, "FFF8E7");
  sl.addText("⭐ Teaching Point: Insidious onset (3+ weeks) of low-grade fever + arthralgias + fatigue without obvious infection source = classic Subacute Bacterial Endocarditis (SBE). Viridans streptococci are the hallmark organism.", {
    x:0.5, y:5.45, w:12.4, h:0.8, fontSize:9.5, fontFace:"Calibri", color:"7A4A00"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 3 – CLINICAL SIGNS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Physical Examination – Clinical Signs", "Slide 3 of 18");

  // Vascular phenomena box
  card(sl, 0.3, 1.25, 6.2, 2.8, "FFF0F0");
  sectionLabel(sl, "VASCULAR PHENOMENA", 0.3, 1.25, 6.2);
  const vRows = [
    [{ text:"Sign", options:{bold:true, color:C.white, fill:{color:C.red}} }, { text:"Finding", options:{bold:true, color:C.white, fill:{color:C.red}} }],
    ["Splinter hemorrhages", "Under nails, 3–4 fingers bilateral"],
    ["Janeway lesions", "Non-tender erythematous macules – palms & soles"],
    ["Arterial emboli", "Evidence on imaging (splenic infarct Day 6)"],
  ];
  sl.addTable(vRows, { x:0.3, y:1.6, w:6.2, h:2.3, colW:[2.5,3.7], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.52 });

  // Immunologic phenomena box
  card(sl, 6.9, 1.25, 6.1, 2.8, "F0FFF5");
  sectionLabel(sl, "IMMUNOLOGIC PHENOMENA", 6.9, 1.25, 6.1);
  const iRows = [
    [{ text:"Sign", options:{bold:true, color:C.white, fill:{color:C.green}} }, { text:"Finding", options:{bold:true, color:C.white, fill:{color:C.green}} }],
    ["Osler nodes", "Tender subcutaneous nodules – fingertips"],
    ["Roth spots", "Flame-shaped retinal hemorrhages (fundoscopy)"],
    ["Glomerulonephritis", "Hematuria + 2+ proteinuria on urinalysis"],
    ["Rheumatoid factor", "Weakly positive"],
  ];
  sl.addTable(iRows, { x:6.9, y:1.6, w:6.1, h:2.3, colW:[2.3,3.8], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.52 });

  // Vitals / cardiac
  card(sl, 0.3, 4.2, 12.7, 1.5);
  sectionLabel(sl, "VITALS & CARDIOVASCULAR", 0.3, 4.2, 12.7);
  const vitalRows = [
    [
      { text:"Temp", options:{bold:true, fill:{color:C.ltTeal}} },
      { text:"Pulse", options:{bold:true, fill:{color:C.ltTeal}} },
      { text:"BP", options:{bold:true, fill:{color:C.ltTeal}} },
      { text:"RR", options:{bold:true, fill:{color:C.ltTeal}} },
      { text:"SpO2", options:{bold:true, fill:{color:C.ltTeal}} },
      { text:"Murmur", options:{bold:true, fill:{color:C.ltTeal}} },
    ],
    ["38.4°C", "96/min", "110/70 mmHg", "20/min", "96% RA", "Pansystolic Gr III/VI at apex → axilla (Mitral Regurg)"],
  ];
  sl.addTable(vitalRows, { x:0.3, y:4.55, w:12.7, h:1.0, colW:[1.8,1.8,2.0,1.6,1.6,3.9], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.45 });

  // Splenomegaly note
  sl.addText("+ Mild splenomegaly (chronic bacteremia)", { x:0.4, y:5.7, w:8, h:0.35, fontSize:9.5, color:C.slate, italic:true, fontFace:"Calibri" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 4 – INVESTIGATIONS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Investigations", "Slide 4 of 18");

  // Lab results
  card(sl, 0.3, 1.25, 5.5, 4.3);
  sectionLabel(sl, "LABORATORY RESULTS", 0.3, 1.25, 5.5);
  const labRows = [
    [{ text:"Test", options:{bold:true, color:C.white, fill:{color:C.teal}} }, { text:"Value", options:{bold:true, color:C.white, fill:{color:C.teal}} }, { text:"Significance", options:{bold:true, color:C.white, fill:{color:C.teal}} }],
    ["Hb", "9.8 g/dL ↓", "Anemia of infection"],
    ["WBC", "12,400/mm³ ↑", "Leukocytosis"],
    ["CRP", "68 mg/L ↑", "Active inflammation"],
    ["ESR", "78 mm/hr ↑", "Elevated"],
    ["RF", "Weakly +ve", "Immunologic criterion"],
    [{ text:"S. Creatinine", options:{bold:true} }, { text:"0.9 mg/dL (BASELINE)", options:{color:C.green, bold:true} }, "Critical for TDM calculations"],
    ["Urinalysis", "Hematuria + 2+ protein", "Immune glomerulonephritis"],
  ];
  sl.addTable(labRows, { x:0.3, y:1.6, w:5.5, h:3.8, colW:[1.6,1.8,2.1], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.46 });

  // Blood cultures
  card(sl, 6.15, 1.25, 6.85, 2.5, "F0FFF5");
  sectionLabel(sl, "BLOOD CULTURE REPORT (KEY)", 6.15, 1.25, 6.85);
  sl.addText([
    { text:"3 sets drawn from separate sites, 30 min apart, BEFORE antibiotics\n", options:{bold:true, breakLine:true} },
    { text:"Organism: ", options:{bold:true} },
    { text:"Streptococcus viridans", options:{italic:true} },
    { text:" (alpha-hemolytic)\n", options:{breakLine:true} },
    { text:"All 3 sets positive ", options:{bold:true, color:C.red} },
    { text:"(Sets 1–3: growth at 18, 22, 24 hrs)\n\n", options:{breakLine:true} },
    { text:"MIC – Penicillin G: ", options:{bold:true} },
    { text:"0.08 µg/mL  →  ≤ 0.12 µg/mL = HIGHLY SUSCEPTIBLE ✅", options:{bold:true, color:C.green} },
  ], { x:6.25, y:1.65, w:6.6, h:2.0, fontSize:10, fontFace:"Calibri", color:C.navy, valign:"top" });

  // Sensitivity table
  card(sl, 6.15, 3.85, 6.85, 1.8);
  sectionLabel(sl, "SENSITIVITY PROFILE", 6.15, 3.85, 6.85);
  const sensRows = [
    [{ text:"Antibiotic", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"MIC", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Interpretation", options:{bold:true, fill:{color:C.navy}, color:C.white} }],
    ["Penicillin G", { text:"0.08 µg/mL", options:{bold:true, color:C.green} }, { text:"SUSCEPTIBLE (Highly)", options:{color:C.green} }],
    ["Ceftriaxone", "0.04 µg/mL", { text:"Susceptible", options:{color:C.green} }],
    ["Vancomycin", "0.5 µg/mL", { text:"Susceptible", options:{color:C.green} }],
    ["Gentamicin", "4 µg/mL", { text:"Susceptible (synergy)", options:{color:C.teal} }],
  ];
  sl.addTable(sensRows, { x:6.15, y:4.2, w:6.85, h:1.35, colW:[2.2,1.7,2.95], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.26 });

  // Echo note
  card(sl, 0.3, 5.6, 12.7, 0.75, C.ltTeal);
  sl.addText("🔊  Echocardiography (TEE): Oscillating vegetation 8mm×6mm on posterior mitral leaflet | No perivalvular abscess | EF = 58%  →  Major Duke Criterion ✅", {
    x:0.5, y:5.65, w:12.4, h:0.65, fontSize:10, fontFace:"Calibri", color:C.navy, bold:false
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 5 – DUKE CRITERIA
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Diagnosis – Modified Duke Criteria", "Slide 5 of 18 | Source: Washington Manual / Fuster & Hurst 15E");

  // Verdict banner
  sl.addShape(pres.shapes.RECTANGLE, { x:0.3, y:1.2, w:12.7, h:0.7, fill:{color:C.green}, line:{color:C.green} });
  sl.addText("VERDICT: DEFINITE INFECTIVE ENDOCARDITIS  (2 Major Criteria Satisfied)", {
    x:0.3, y:1.2, w:12.7, h:0.7, fontSize:16, bold:true, color:C.white, align:"center", fontFace:"Calibri"
  });

  // Major criteria
  card(sl, 0.3, 2.0, 12.7, 2.0, "E8F8F0");
  sectionLabel(sl, "MAJOR CRITERIA  (2 of 2 satisfied = DEFINITE IE)", 0.3, 2.0, 12.7);
  const majRows = [
    [
      { text:"#", options:{bold:true, fill:{color:C.green}, color:C.white} },
      { text:"Criterion", options:{bold:true, fill:{color:C.green}, color:C.white} },
      { text:"Evidence in this patient", options:{bold:true, fill:{color:C.green}, color:C.white} },
      { text:"Status", options:{bold:true, fill:{color:C.green}, color:C.white} },
    ],
    ["1", "Positive blood cultures – typical organism (S. viridans) from ≥2 separate cultures",
      "All 3 blood culture sets positive for S. viridans (drawn >12 hrs apart)",
      { text:"✅ PRESENT", options:{bold:true, color:C.green} }],
    ["2", "Echocardiographic evidence – oscillating vegetation on valve",
      "8mm vegetation on mitral posterior leaflet (TEE confirmed)",
      { text:"✅ PRESENT", options:{bold:true, color:C.green} }],
  ];
  sl.addTable(majRows, { x:0.3, y:2.35, w:12.7, h:1.55, colW:[0.4,4.6,6.2,1.5], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.48 });

  // Minor criteria
  card(sl, 0.3, 4.1, 12.7, 2.25);
  sectionLabel(sl, "MINOR CRITERIA  (4 of 5 additionally present)", 0.3, 4.1, 12.7);
  const minRows = [
    [
      { text:"Minor Criterion", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Evidence", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Status", options:{bold:true, fill:{color:C.teal}, color:C.white} },
    ],
    ["Predisposing heart condition", "Rheumatic Heart Disease with mitral regurgitation", { text:"✅", options:{color:C.green, bold:true} }],
    ["Fever ≥ 38°C", "38.4°C on admission", { text:"✅", options:{color:C.green, bold:true} }],
    ["Vascular phenomena", "Splinter hemorrhages, Janeway lesions", { text:"✅", options:{color:C.green, bold:true} }],
    ["Immunologic phenomena", "Osler nodes, Roth spots, weakly positive RF", { text:"✅", options:{color:C.green, bold:true} }],
  ];
  sl.addTable(minRows, { x:0.3, y:4.45, w:12.7, h:1.8, colW:[3.2,8.0,1.5], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.43 });

  sl.addText("Reference: Li JS et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-638", {
    x:0.3, y:6.4, w:12, h:0.3, fontSize:8, color:C.midGray, italic:true, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 6 – PATHOPHYSIOLOGY
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Pathophysiology of Infective Endocarditis", "Slide 6 of 18");

  card(sl, 0.3, 1.2, 12.7, 4.8);

  // Flowchart using shapes + text
  const steps = [
    { label:"Dental Extraction", sub:"Transient bacteremia with S. viridans" },
    { label:"Enters Bloodstream", sub:"Bacteremia – organism circulates" },
    { label:"Damaged Valve Endothelium", sub:"RHD → exposed subendothelial collagen" },
    { label:"Bacterial Adherence", sub:"Fibrin-platelet thrombus → bacteria colonize" },
    { label:"Vegetation Formation", sub:"Bacteria + fibrin + platelets → 8mm mass" },
  ];

  const bx = 0.6, by = 1.4, bw = 2.2, bh = 0.7, gap = 0.55;
  steps.forEach((s, i) => {
    const xpos = bx + i*(bw + gap);
    sl.addShape(pres.shapes.RECTANGLE, { x:xpos, y:by, w:bw, h:bh, fill:{color:C.teal}, line:{color:C.teal} });
    sl.addText(s.label, { x:xpos, y:by+0.03, w:bw, h:0.35, fontSize:9.5, bold:true, color:C.white, align:"center", fontFace:"Calibri" });
    sl.addText(s.sub, { x:xpos, y:by+0.37, w:bw, h:0.3, fontSize:7.5, color:"CCE8F4", align:"center", fontFace:"Calibri" });
    if (i < steps.length-1) {
      sl.addText("→", { x:xpos+bw, y:by+0.15, w:gap, h:0.4, fontSize:16, color:C.gold, align:"center", fontFace:"Calibri" });
    }
  });

  // Consequences
  const cons = [
    { title:"Local Effects", color:C.red, items:["Valve leaflet destruction", "Worsening mitral regurgitation", "Risk of congestive heart failure"] },
    { title:"Embolic Effects", color:C.gold, items:["Vegetation fragments embolise", "Brain → stroke / cerebral abscess", "Kidney / spleen → infarcts"] },
    { title:"Immune Effects", color:C.teal, items:["Circulating immune complexes", "Glomerulonephritis (hematuria)", "Osler nodes, Roth spots"] },
  ];

  cons.forEach((c, i) => {
    const cx = 0.5 + i * 4.3;
    card(sl, cx, 2.5, 4.1, 2.55, "FAFCFF");
    sl.addShape(pres.shapes.RECTANGLE, { x:cx, y:2.5, w:4.1, h:0.38, fill:{color:c.color}, line:{color:c.color} });
    sl.addText(c.title, { x:cx, y:2.5, w:4.1, h:0.38, fontSize:10.5, bold:true, color:C.white, align:"center", fontFace:"Calibri" });
    sl.addText(c.items.map(it => "• " + it).join("\n"), {
      x:cx+0.1, y:2.95, w:3.9, h:1.9, fontSize:10, color:C.navy, fontFace:"Calibri", valign:"top"
    });
  });

  // PharmD note
  card(sl, 0.3, 5.3, 12.7, 0.85, "FFF8E7");
  sl.addText("🔑  PharmD Key Concept: IE vegetations are avascular fibrin-platelet matrices with bacteria in metabolically low-activity state at high density. This is WHY bactericidal therapy (not bacteriostatic) is mandatory — bacteriostatic drugs cannot kill organisms in this protected, poorly-perfused environment.",
    { x:0.5, y:5.35, w:12.4, h:0.75, fontSize:9.5, color:"7A4A00", fontFace:"Calibri" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 7 – TREATMENT GOALS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Treatment Goals", "Slide 7 of 18");

  const goals = [
    { num:"01", title:"Eradicate the organism", detail:"Complete bactericidal elimination of S. viridans from the vegetation – requires prolonged IV therapy", color:C.teal },
    { num:"02", title:"Prevent valve destruction", detail:"Stop progressive leaflet erosion from active infection – prevent acute severe MR", color:C.navy },
    { num:"03", title:"Prevent systemic emboli", detail:"Reduce vegetation burden to prevent embolism to brain, kidney, spleen", color:C.red },
    { num:"04", title:"Manage heart failure", detail:"Treat fluid overload secondary to mitral regurgitation (Furosemide)", color:"6B48B5" },
    { num:"05", title:"Ensure adequate duration", detail:"4-week minimum for highly susceptible strains (NVE); 6 weeks if complicated", color:C.green },
    { num:"06", title:"Prevent recurrence", detail:"Lifelong antibiotic prophylaxis before dental / invasive procedures", color:C.gold },
  ];

  goals.forEach((g, i) => {
    const col = i < 3 ? 0 : 1;
    const row = i % 3;
    const gx = 0.3 + col * 6.6;
    const gy = 1.3 + row * 1.75;
    card(sl, gx, gy, 6.3, 1.6);
    sl.addShape(pres.shapes.RECTANGLE, { x:gx, y:gy, w:0.85, h:1.6, fill:{color:g.color}, line:{color:g.color} });
    sl.addText(g.num, { x:gx, y:gy+0.45, w:0.85, h:0.7, fontSize:22, bold:true, color:C.white, align:"center", fontFace:"Calibri" });
    sl.addText(g.title, { x:gx+0.95, y:gy+0.15, w:5.2, h:0.45, fontSize:12, bold:true, color:C.navy, fontFace:"Calibri", margin:0 });
    sl.addText(g.detail, { x:gx+0.95, y:gy+0.6, w:5.2, h:0.85, fontSize:9.5, color:C.slate, fontFace:"Calibri", valign:"top" });
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 8 – EMPIRIC THERAPY (Day 1–2)
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Pharmacotherapy – Empiric Therapy (Day 1–2)", "Slide 8 of 18 | Before culture report");

  card(sl, 0.3, 1.2, 12.7, 0.75, C.ltTeal);
  sl.addText("Clinical situation: Patient is clinically stable (SBE pattern). Blood cultures drawn → Empiric IV vancomycin started while awaiting culture + susceptibility.", {
    x:0.5, y:1.25, w:12.4, h:0.65, fontSize:10.5, color:C.navy, fontFace:"Calibri"
  });

  // Drug 1 – Vancomycin
  card(sl, 0.3, 2.1, 12.7, 3.2);
  sectionLabel(sl, "DRUG 1 — VANCOMYCIN  (Empiric, Days 1–2)", 0.3, 2.1, 12.7);

  const vancoRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Details", options:{bold:true, fill:{color:C.navy}, color:C.white} }],
    ["Indication", "Empiric broad-spectrum cover (MRSA / Strep / Enterococcus) before culture results"],
    [{ text:"Dose", options:{bold:true} }, { text:"15 mg/kg IV q12h  →  65 kg × 15 = 975 mg IV q12h", options:{bold:true, color:C.teal} }],
    ["Route & Infusion", "IV infusion over 60 min (slow rate to avoid Red Man Syndrome)"],
    ["Mechanism", "Inhibits cell wall synthesis by binding D-Ala-D-Ala terminal of peptidoglycan precursor"],
    [{ text:"TDM Target", options:{bold:true} }, { text:"Trough: 10–15 µg/mL  |  Day 2 result: 12 µg/mL ✅  Within range", options:{color:C.green} }],
    [{ text:"Why stopped Day 3?", options:{bold:true, color:C.red} }, "Culture confirmed S. viridans susceptible to Penicillin G → De-escalate (Antibiotic Stewardship principle)"],
    ["ADRs to Monitor", "Red Man Syndrome (rapid infusion), Nephrotoxicity, Ototoxicity"],
  ];
  sl.addTable(vancoRows, { x:0.3, y:2.45, w:12.7, h:2.75, colW:[2.6,10.1], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.34 });

  card(sl, 0.3, 5.35, 12.7, 0.8, "FFF0F0");
  sl.addText("⚠  Antibiotic Stewardship Point: Vancomycin is not superior to Penicillin G for susceptible Streptococcal IE. Once culture confirms susceptibility, always de-escalate to Penicillin G. Vancomycin carries higher nephrotoxicity risk than Penicillin.", {
    x:0.5, y:5.4, w:12.4, h:0.7, fontSize:9.5, color:C.red, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 9 – DEFINITIVE THERAPY (Drug 2 – Penicillin G)
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Pharmacotherapy – Definitive Therapy: Penicillin G", "Slide 9 of 18 | Day 3 onwards | Source: Fuster & Hurst Table 33-9; Washington Manual Table 14-7");

  card(sl, 0.3, 1.2, 12.7, 0.7, "E8F8F0");
  sl.addText("Organism: S. viridans  |  MIC Penicillin G: 0.08 µg/mL (≤ 0.12 = Highly Susceptible)  →  Regimen: Penicillin G + Gentamicin for 2 weeks, then Penicillin G alone for weeks 3–4", {
    x:0.5, y:1.25, w:12.4, h:0.6, fontSize:10.5, bold:true, color:C.green, fontFace:"Calibri"
  });

  // Drug 2 table
  card(sl, 0.3, 2.0, 12.7, 3.5);
  sectionLabel(sl, "DRUG 2 — AQUEOUS CRYSTALLINE PENICILLIN G  (Definitive, Day 3 → 4 weeks total)", 0.3, 2.0, 12.7);

  const penRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Details", options:{bold:true, fill:{color:C.navy}, color:C.white} }],
    ["Indication", "Definitive therapy for S. viridans NVE – MIC ≤ 0.12 µg/mL (highly penicillin-susceptible)"],
    [{ text:"Dose", options:{bold:true} }, { text:"3 million units IV q4h  (= 18 million units/day total)", options:{bold:true, color:C.teal} }],
    ["Route", "IV – divided doses q4h (or continuous IV infusion)"],
    ["Duration", "Started Day 3 → 4 weeks total (2-week Pen G + Gentamicin combo, then Pen G alone for weeks 3–4)"],
    ["Mechanism", "Beta-lactam → irreversibly binds Penicillin Binding Proteins (PBPs) → inhibits transpeptidation → cell wall lysis → bactericidal"],
    ["Why Pen G over Amoxicillin?", "Higher bactericidal potency for S. viridans; parenteral route ensures reliable & consistently high plasma levels"],
    ["If Penicillin allergic (mild)", "Ceftriaxone 2g IV once daily × 4 weeks"],
    ["If true PCN anaphylaxis", "Vancomycin 30 mg/kg/day in 2 doses × 4 weeks (no gentamicin needed)"],
    ["ADRs", "Hypersensitivity (ask allergy Hx), Hypokalemia (large doses of K-penicillin), Neurotoxicity (very high doses)"],
    ["Drug Interaction", "Probenecid blocks renal tubular secretion → ↑ Penicillin G plasma levels (not co-prescribed here)"],
  ];
  sl.addTable(penRows, { x:0.3, y:2.35, w:12.7, h:3.1, colW:[2.8,9.9], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.27 });

  sl.addText("OPAT = Outpatient Parenteral Antibiotic Therapy. Patient discharged Day 5 with Penicillin G continuing via OPAT for remaining 3 weeks.", {
    x:0.3, y:5.6, w:12.7, h:0.5, fontSize:9, color:C.midGray, italic:true, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 10 – DRUG 3: GENTAMICIN
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Pharmacotherapy – Drug 3: Gentamicin (Synergistic)", "Slide 10 of 18 | Days 3–14 | Source: Harrison's 22E; Goldman-Cecil");

  card(sl, 0.3, 1.2, 12.7, 3.8);
  sectionLabel(sl, "DRUG 3 — GENTAMICIN SULFATE  (Synergistic combination, first 2 weeks only)", 0.3, 1.2, 12.7);

  const gentRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Details", options:{bold:true, fill:{color:C.navy}, color:C.white} }],
    ["Indication", "Synergistic combination with Penicillin G to enhance bactericidal killing of S. viridans"],
    [{ text:"Dose Calculation", options:{bold:true} }, { text:"3 mg/kg/day  →  65 kg × 3 = 195 mg/day  ÷  3 doses  =  65 mg IV q8h", options:{bold:true, color:C.teal} }],
    ["Route", "IV over 30 minutes"],
    ["Duration", "FIRST 2 WEEKS ONLY (Days 3–14 of therapy) → then stopped"],
    ["Mechanism", "Aminoglycoside → binds 30S ribosomal subunit → misreading of mRNA → concentration-dependent bactericidal killing"],
    ["Synergy Mechanism", "Penicillin G disrupts cell wall → Gentamicin gains greatly enhanced entry into cell → synergistic bacterial kill"],
    ["Why only 2 weeks?", "Synergistic benefit achieved in first 2 weeks; continuing longer ↑ ototoxicity + nephrotoxicity with no added clinical benefit"],
  ];
  sl.addTable(gentRows, { x:0.3, y:1.55, w:12.7, h:3.4, colW:[2.7,10.0], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.4 });

  // Toxicity box
  card(sl, 0.3, 5.1, 6.1, 1.15, "FFF0F0");
  sectionLabel(sl, "NEPHROTOXICITY", 0.3, 5.1, 6.1);
  sl.addText("Tubular cell injury → rising SCr, oliguria\nReversible if caught early via TDM monitoring\nRisk factors: trough > 1 µg/mL, dehydration, NSAIDs", {
    x:0.4, y:5.45, w:5.9, h:0.75, fontSize:9.5, color:C.navy, fontFace:"Calibri"
  });

  card(sl, 6.8, 5.1, 6.2, 1.15, "FFF0F0");
  sectionLabel(sl, "OTOTOXICITY  (IRREVERSIBLE)", 6.8, 5.1, 6.2);
  sl.addText("Cochlear hair cell destruction → hearing loss, tinnitus\nIRREVERSIBLE – cannot be undone once it occurs\nRisk: cumulative dose, loop diuretics, prior aminoglycoside", {
    x:6.95, y:5.45, w:5.95, h:0.75, fontSize:9.5, color:C.red, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 11 – TDM (Gentamicin)
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Therapeutic Drug Monitoring – Gentamicin TDM", "Slide 11 of 18 | PharmD-Specific Role | Source: Harrison's 22E · Goldman-Cecil");

  // Why TDM
  card(sl, 0.3, 1.2, 12.7, 0.9, C.ltTeal);
  sl.addText("Why TDM for Gentamicin? Narrow therapeutic index (toxic ≈ therapeutic dose). Two irreversible toxicities: Nephrotoxicity (tubular) + Ototoxicity (cochlear). Toxicity is trough-dependent (accumulation). TDM is the primary tool to individualise dosing — core PharmD competency.", {
    x:0.5, y:1.25, w:12.4, h:0.8, fontSize:10, color:C.navy, fontFace:"Calibri"
  });

  // Target levels
  card(sl, 0.3, 2.2, 6.1, 2.2);
  sectionLabel(sl, "TARGET SERUM LEVELS", 0.3, 2.2, 6.1);
  const lvlRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.teal}, color:C.white} }, { text:"Target", options:{bold:true, fill:{color:C.teal}, color:C.white} }, { text:"Sampling Time", options:{bold:true, fill:{color:C.teal}, color:C.white} }],
    [{ text:"Peak", options:{bold:true} }, { text:"3.0 – 3.5 µg/mL", options:{bold:true, color:C.green} }, "1 hr AFTER 30-min IV infusion"],
    [{ text:"Trough", options:{bold:true} }, { text:"< 1.0 µg/mL", options:{bold:true, color:C.green} }, "30 min BEFORE next dose"],
  ];
  sl.addTable(lvlRows, { x:0.3, y:2.55, w:6.1, h:1.7, colW:[1.6,2.0,2.5], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.54 });

  // Steady state note
  card(sl, 6.75, 2.2, 6.25, 2.2);
  sectionLabel(sl, "WHEN TO DRAW LEVELS", 6.75, 2.2, 6.25);
  sl.addText([
    { text:"First level: ", options:{bold:true} }, { text:"After 3rd or 4th dose (steady state ≈ 5 half-lives ≈ 10–15 hrs)\n", options:{breakLine:true} },
    { text:"Subsequent: ", options:{bold:true} }, { text:"Every 3–4 days if stable; more frequently if renal function changes\n", options:{breakLine:true} },
    { text:"Renal impairment: ", options:{bold:true} }, { text:"Daily monitoring required", options:{} },
  ], { x:6.85, y:2.58, w:6.0, h:1.6, fontSize:10, fontFace:"Calibri", color:C.navy, valign:"top" });

  // Day 5 TDM scenario
  card(sl, 0.3, 4.5, 12.7, 1.75);
  sectionLabel(sl, "DAY 5 TDM SCENARIO – Dose Adjustment (Pharmacist Action)", 0.3, 4.5, 12.7);
  const tdmRows = [
    [
      { text:"Sample", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Day 5 Result", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Target", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Interpretation", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Pharmacist Action", options:{bold:true, fill:{color:C.navy}, color:C.white} },
    ],
    ["Peak (1 hr post-dose)", { text:"4.8 µg/mL ❌", options:{bold:true, color:C.red} }, "3.0–3.5 µg/mL", { text:"ELEVATED", options:{color:C.red, bold:true} }, "Reduce dose"],
    ["Trough (pre-dose)", { text:"1.4 µg/mL ❌", options:{bold:true, color:C.red} }, "< 1 µg/mL", { text:"ELEVATED", options:{color:C.red, bold:true} }, "Increase interval"],
    ["S. Creatinine", { text:"1.1 mg/dL (rising)", options:{color:C.gold, bold:true} }, "0.7–1.2 mg/dL", { text:"RISING from baseline 0.9", options:{color:C.gold} }, "Monitor daily – early nephrotoxicity risk"],
  ];
  sl.addTable(tdmRows, { x:0.3, y:4.85, w:12.7, h:1.3, colW:[2.2,1.9,1.8,2.3,4.5], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.41 });

  sl.addText("Revised dose → 55 mg q8h  |  Recheck peak/trough after 3 doses  |  Day 8 levels: Peak 3.2 ✅  Trough 0.7 ✅  SCr 0.9 (back to baseline) ✅", {
    x:0.3, y:6.3, w:12.7, h:0.4, fontSize:10, bold:true, color:C.green, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 12 – DRUGS 4 & 5
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Pharmacotherapy – Drugs 4 & 5: Furosemide & Paracetamol", "Slide 12 of 18");

  // Drug 4 – Furosemide
  card(sl, 0.3, 1.2, 12.7, 2.6);
  sectionLabel(sl, "DRUG 4 — FUROSEMIDE  (Day 3–5, then oral at discharge)", 0.3, 1.2, 12.7);
  const furoRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:"6B48B5"}, color:C.white} }, { text:"Details", options:{bold:true, fill:{color:"6B48B5"}, color:C.white} }],
    ["Indication", "Fluid overload / pulmonary congestion secondary to mitral regurgitation (worsened by active IE)"],
    [{ text:"Dose", options:{bold:true} }, { text:"20 mg IV OD (Days 3–5) → 20 mg oral OD at discharge", options:{bold:true, color:C.teal} }],
    ["Mechanism", "Loop diuretic: Inhibits Na⁺/K⁺/2Cl⁻ cotransporter in thick ascending loop of Henle → natriuresis, diuresis → ↓ preload → relieves pulmonary congestion"],
    ["Monitoring", "Urine output (target >0.5 mL/kg/hr), Serum K⁺ (hypokalemia), BP (hypotension), SCr"],
    [{ text:"⚠ Critical Interaction", options:{bold:true, color:C.red} }, { text:"Furosemide + Gentamicin = ADDITIVE OTOTOXICITY — both damage cochlear cells. Use lowest effective Furosemide dose and monitor hearing.", options:{color:C.red} }],
    ["ADRs", "Hypokalemia (supplement KCl if K⁺ < 3.5), hyponatremia, dehydration, hyperuricemia"],
  ];
  sl.addTable(furoRows, { x:0.3, y:1.55, w:12.7, h:2.15, colW:[2.5,10.2], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.3 });

  // Drug 5 – Paracetamol
  card(sl, 0.3, 3.9, 12.7, 2.4);
  sectionLabel(sl, "DRUG 5 — PARACETAMOL (Acetaminophen)  (Days 1–5 PRN)", 0.3, 3.9, 12.7);
  const paraRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.gold}, color:C.white} }, { text:"Details", options:{bold:true, fill:{color:C.gold}, color:C.white} }],
    ["Indication", "Fever (38.4°C) + arthralgias – symptomatic relief"],
    [{ text:"Dose", options:{bold:true} }, { text:"500 mg – 1g oral/IV q6–8h PRN  |  Max: 4g/day", options:{bold:true, color:C.teal} }],
    ["Mechanism", "Central inhibition of prostaglandin synthesis (COX in CNS) + activation of descending serotonergic pathways → antipyretic + analgesic"],
    [{ text:"Why NOT NSAIDs?", options:{bold:true, color:C.red} }, { text:"NSAIDs: ↓ platelet function (↑ hemorrhagic risk from emboli), nephrotoxic (additive with Gentamicin), mask fever (monitoring parameter). CONTRAINDICATED in IE.", options:{color:C.red} }],
    ["Monitoring", "LFT if prolonged use; avoid in hepatic impairment; max dose adherence"],
  ];
  sl.addTable(paraRows, { x:0.3, y:4.25, w:12.7, h:1.9, colW:[2.5,10.2], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.37 });

  sl.addText("Day 1: Temp 38.4°C → Paracetamol given  |  Day 2: Temp reduced to 37.6°C ✅  |  Day 5: Afebrile – Paracetamol stopped", {
    x:0.3, y:6.37, w:12.7, h:0.35, fontSize:9, color:C.midGray, italic:true, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 13 – 5-DAY TIMELINE
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "5-Day Clinical Timeline – All Events & Drugs", "Slide 13 of 18");

  const tlRows = [
    [
      { text:"", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"DAY 1", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"DAY 2", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"DAY 3", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"DAY 4", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"DAY 5", options:{bold:true, fill:{color:C.navy}, color:C.white} },
    ],
    [{ text:"Clinical Status", options:{bold:true, fill:{color:C.ltTeal}} }, "Febrile 38.4°C\nMurmur++\nSplinter hemor.", "Fever 38.1°C\nSpO2 94%\nCrepitations", "Afebrile 37.4°C\nCrepitations mild", "Afebrile\nFeeling better\nSpO2 96%", "Stable\nAfebrile\nSpO2 97%"],
    [{ text:"Culture Report", options:{bold:true, fill:{color:C.ltTeal}} }, "Sent (pending)", { text:"S. viridans\nisolated", options:{bold:true} }, "MIC confirmed\n0.08 µg/mL", "Sensitivity\nconfirmed", "All 3 sets\nconfirmed"],
    [{ text:"Drug 1\nVancomycin", options:{bold:true, fill:{color:"E8E0F4"}, color:"4B0082"} }, { text:"975 mg IV q12h\n▶ START", options:{color:"4B0082", bold:true} }, { text:"975 mg IV q12h\nTrough: 12 ✅", options:{color:"4B0082"} }, { text:"⏹ STOPPED\n(De-escalate)", options:{bold:true, color:C.red} }, "—", "—"],
    [{ text:"Drug 2\nPenicillin G", options:{bold:true, fill:{color:"E0F4E8"}, color:C.green} }, "—", "—", { text:"3 MU q4h IV\n▶ START", options:{bold:true, color:C.green} }, { text:"3 MU q4h IV\n(Continue)", options:{color:C.green} }, { text:"3 MU q4h IV\n→ OPAT Discharge", options:{color:C.green, bold:true} }],
    [{ text:"Drug 3\nGentamicin", options:{bold:true, fill:{color:"E0EEF8"}, color:C.teal} }, "—", "—", { text:"65 mg q8h IV\n▶ START", options:{bold:true, color:C.teal} }, { text:"65 mg q8h IV\nTDM scheduled", options:{color:C.teal} }, { text:"→ 55 mg q8h ⚠\nTDM: Peak 4.8❌\nTrough 1.4❌", options:{color:C.red, bold:true} }],
    [{ text:"Drug 4\nFurosemide", options:{bold:true, fill:{color:"EDE8F8"}, color:"6B48B5"} }, "—", "—", { text:"20 mg IV OD\n▶ START", options:{bold:true, color:"6B48B5"} }, "20 mg IV OD", { text:"20 mg oral OD\n(Discharge)", options:{color:"6B48B5"} }],
    [{ text:"Drug 5\nParacetamol", options:{bold:true, fill:{color:"FFF4E0"}, color:C.gold} }, { text:"500 mg q6h PRN\n▶ START", options:{bold:true, color:C.gold} }, "500 mg q6h PRN", "500 mg q8h PRN", "PRN (once)", { text:"⏹ STOPPED\n(Afebrile)", options:{bold:true, color:C.red} }],
    [{ text:"Pharmacist Action", options:{bold:true, fill:{color:C.teal}, color:C.white} }, "Empiric regimen\nrecommendation\nVanco TDM plan", "Vancomycin\ntrough check\n(12 ✅)", "Dose calc:\nPen G + Genta\nCounselling", "Monitoring\nTDM scheduled\nADR check", { text:"TDM interpret\nDose ↓ Gentamicin\nDischarge counsel", options:{bold:true} }],
  ];
  sl.addTable(tlRows, {
    x:0.2, y:1.2, w:12.9, h:6.05,
    colW:[1.65,2.1,2.1,2.1,2.2,2.75],
    border:{pt:0.5, color:C.ltGray},
    fontSize:8.5, fontFace:"Calibri",
    rowH:0.65
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 14 – DRUG INTERACTIONS & TDM SUMMARY CARD
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Drug Interactions & TDM Summary Card", "Slide 14 of 18");

  // Drug interactions
  card(sl, 0.3, 1.2, 12.7, 3.0);
  sectionLabel(sl, "DRUG INTERACTION TABLE", 0.3, 1.2, 12.7);
  const diRows = [
    [
      { text:"Drug Pair", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Type of Interaction", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Clinical Significance", options:{bold:true, fill:{color:C.navy}, color:C.white} },
      { text:"Management", options:{bold:true, fill:{color:C.navy}, color:C.white} },
    ],
    ["Gentamicin + Furosemide", { text:"Additive Ototoxicity", options:{color:C.red, bold:true} }, { text:"HIGH – both damage cochlear hair cells independently", options:{color:C.red} }, "Use lowest Furosemide dose; monitor hearing daily"],
    ["Gentamicin + Vancomycin\n(Days 1–2 overlap)", { text:"Additive Nephrotoxicity", options:{color:C.gold, bold:true} }, { text:"MODERATE – both nephrotoxic; renal tubular injury risk", options:{color:C.gold} }, "Monitor SCr daily; Vancomycin stopped Day 3"],
    ["Penicillin G + Probenecid", "Probenecid blocks renal secretion → ↑ Pen G levels", "LOW (potentially beneficial if used intentionally)", "Not co-prescribed here; note for reference"],
    ["Furosemide + Penicillin G", "Furosemide → hypokalemia → altered drug disposition", "LOW", "Monitor electrolytes (K⁺) daily"],
  ];
  sl.addTable(diRows, { x:0.3, y:1.55, w:12.7, h:2.55, colW:[2.8,2.8,3.8,3.3], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.6 });

  // TDM summary card
  card(sl, 0.3, 4.3, 12.7, 2.0);
  sectionLabel(sl, "TDM QUICK REFERENCE CARD", 0.3, 4.3, 12.7);
  const tdmSumRows = [
    [
      { text:"Drug", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Target Peak", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Target Trough", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Day 2 Result", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Day 5 Result", options:{bold:true, fill:{color:C.teal}, color:C.white} },
      { text:"Action Taken", options:{bold:true, fill:{color:C.teal}, color:C.white} },
    ],
    [{ text:"Vancomycin", options:{bold:true} }, "—", "10–15 µg/mL", { text:"12 µg/mL ✅", options:{color:C.green} }, "N/A (stopped Day 3)", "Maintained → De-escalated to Penicillin G"],
    [{ text:"Gentamicin", options:{bold:true} }, "3.0–3.5 µg/mL", "< 1.0 µg/mL", "Not yet drawn", { text:"Peak 4.8 ❌\nTrough 1.4 ❌", options:{color:C.red, bold:true} }, { text:"Dose reduced\n65 mg → 55 mg q8h", options:{bold:true, color:C.teal} }],
  ];
  sl.addTable(tdmSumRows, { x:0.3, y:4.65, w:12.7, h:1.55, colW:[1.8,1.8,1.8,1.9,2.1,3.3], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.72 });

  sl.addText("Reference: Harrison's Principles of Internal Medicine 22E (2025) — 'Target peak ~3.5 µg/mL and trough ≤1 µg/mL for divided-dose gentamicin in IE'", {
    x:0.3, y:6.38, w:12.7, h:0.3, fontSize:8, color:C.midGray, italic:true, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 15 – 5 DRUGS SUMMARY CARD
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "5 Drugs at a Glance – Quick Revision Card", "Slide 15 of 18");

  const drugs5 = [
    { num:"1", name:"VANCOMYCIN", days:"Days 1–2", use:"Empiric broad-spectrum (pre-culture)", key:"Trough: 10–15 µg/mL", color:C.navy },
    { num:"2", name:"PENICILLIN G", days:"Day 3 → 4 wks", use:"Definitive (S. viridans MIC 0.08)", key:"Allergy Hx; Hypokalemia", color:C.teal },
    { num:"3", name:"GENTAMICIN", days:"Days 3–14 (2 wks)", use:"Synergy with Penicillin G", key:"Peak 3–3.5 | Trough <1 µg/mL", color:C.green },
    { num:"4", name:"FUROSEMIDE", days:"Days 3–5 → oral", use:"Fluid overload / pulmonary congestion", key:"K⁺, SCr, urine output; Ototox risk w/ Genta", color:"6B48B5" },
    { num:"5", name:"PARACETAMOL", days:"Days 1–5 PRN", use:"Fever + arthralgias (NSAIDs contraindicated)", key:"LFT; max 4g/day", color:C.gold },
  ];

  drugs5.forEach((d, i) => {
    const gy = 1.3 + i * 1.08;
    card(sl, 0.3, gy, 12.7, 1.0);
    sl.addShape(pres.shapes.RECTANGLE, { x:0.3, y:gy, w:0.7, h:1.0, fill:{color:d.color}, line:{color:d.color} });
    sl.addText(d.num, { x:0.3, y:gy+0.25, w:0.7, h:0.5, fontSize:22, bold:true, color:C.white, align:"center", fontFace:"Calibri" });

    sl.addShape(pres.shapes.RECTANGLE, { x:1.0, y:gy, w:2.8, h:1.0, fill:{color:d.color}, line:{color:d.color} });
    sl.addText(d.name, { x:1.0, y:gy+0.1, w:2.8, h:0.5, fontSize:14, bold:true, color:C.white, align:"center", fontFace:"Calibri" });
    sl.addText(d.days, { x:1.0, y:gy+0.6, w:2.8, h:0.35, fontSize:10, color:"D0E8F0", align:"center", fontFace:"Calibri" });

    sl.addText("Why Used:", { x:3.9, y:gy+0.08, w:1.1, h:0.35, fontSize:9, bold:true, color:C.midGray, fontFace:"Calibri" });
    sl.addText(d.use, { x:5.0, y:gy+0.08, w:4.5, h:0.4, fontSize:10.5, color:C.navy, fontFace:"Calibri" });
    sl.addText("Key Monitor:", { x:3.9, y:gy+0.55, w:1.2, h:0.35, fontSize:9, bold:true, color:C.midGray, fontFace:"Calibri" });
    sl.addText(d.key, { x:5.1, y:gy+0.55, w:8.0, h:0.35, fontSize:10, color:C.slate, fontFace:"Calibri" });
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 16 – MONITORING PARAMETERS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Monitoring Parameters", "Slide 16 of 18");

  // Clinical
  card(sl, 0.3, 1.2, 6.2, 2.8);
  sectionLabel(sl, "CLINICAL MONITORING", 0.3, 1.2, 6.2);
  const clinRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.teal}, color:C.white} }, { text:"Frequency", options:{bold:true, fill:{color:C.teal}, color:C.white} }, { text:"Target", options:{bold:true, fill:{color:C.teal}, color:C.white} }],
    ["Temperature", "q6–8h", "Afebrile within 5–7 days"],
    ["Heart rate / BP", "Daily", "Hemodynamic stability"],
    ["Murmur character", "Daily auscultation", "No new murmur / worsening"],
    ["Urine output", "Daily", "> 0.5 mL/kg/hr"],
    ["Embolic signs\n(neuro, flank, vision)", "Every assessment", "Absence"],
    ["HF signs (JVP, edema)", "Daily", "Absence"],
  ];
  sl.addTable(clinRows, { x:0.3, y:1.55, w:6.2, h:2.4, colW:[2.0,1.5,2.7], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.37 });

  // Lab
  card(sl, 6.8, 1.2, 6.2, 2.8);
  sectionLabel(sl, "LABORATORY MONITORING", 6.8, 1.2, 6.2);
  const labRows = [
    [{ text:"Test", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Frequency", options:{bold:true, fill:{color:C.navy}, color:C.white} }, { text:"Reason", options:{bold:true, fill:{color:C.navy}, color:C.white} }],
    ["Blood cultures (repeat)", "48–72 hrs of therapy", "Confirm bacteremia clearance"],
    ["SCr, BUN", "Daily (Gentamicin phase)", "Nephrotoxicity detection"],
    ["Urinalysis", "Every 3 days", "Tubular injury casts"],
    ["CBC", "Twice weekly", "Drug-induced cytopenias"],
    ["CRP, ESR", "Weekly", "Inflammation trend"],
    ["Genta Peak + Trough", "After 3rd dose, then q3–4 days", "TDM – dose individualisation"],
    ["Repeat Echo (TTE)", "Week 2–3 of therapy", "Vegetation resolution assessment"],
  ];
  sl.addTable(labRows, { x:6.8, y:1.55, w:6.2, h:2.4, colW:[2.0,1.6,2.6], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.3 });

  // Ototoxicity
  card(sl, 0.3, 4.1, 12.7, 1.3, "FFF0F0");
  sectionLabel(sl, "OTOTOXICITY MONITORING – GENTAMICIN SPECIFIC", 0.3, 4.1, 12.7);
  const otoRows = [
    [{ text:"What to Ask/Test", options:{bold:true, fill:{color:C.red}, color:C.white} }, { text:"Frequency", options:{bold:true, fill:{color:C.red}, color:C.white} }],
    ["Ask daily: any new hearing difficulty, ringing (tinnitus), dizziness or vertigo", "Every day during Gentamicin therapy"],
    ["Formal audiometry testing", "If any symptom reported (or as baseline before starting)"],
  ];
  sl.addTable(otoRows, { x:0.3, y:4.45, w:12.7, h:0.88, colW:[9.5,3.2], border:{pt:0.5,color:C.ltGray}, fontSize:10, fontFace:"Calibri", rowH:0.4 });

  // Outcome markers
  card(sl, 0.3, 5.45, 12.7, 0.85, C.ltTeal);
  sl.addText("Outcome Markers for Treatment Success: Temperature normal for ≥7 days | Repeat blood cultures negative | CRP trending down | No new embolic events | Vegetation size reducing on echo | Hearing intact", {
    x:0.5, y:5.5, w:12.4, h:0.75, fontSize:10, color:C.navy, fontFace:"Calibri"
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 17 – COMPLICATIONS & ANTIBIOTIC PROPHYLAXIS
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Complications Encountered & Antibiotic Prophylaxis", "Slide 17 of 18");

  // Complications
  card(sl, 0.3, 1.2, 7.8, 4.0);
  sectionLabel(sl, "COMPLICATIONS IN THIS CASE", 0.3, 1.2, 7.8);

  const comps = [
    { title:"1. Early Nephrotoxicity (Day 5)", color:C.red, detail:"SCr rose 0.9 → 1.1 mg/dL.\nCause: Gentamicin (elevated trough 1.4 µg/mL).\nManagement: Dose reduced 65→55 mg q8h.\nOutcome: SCr back to 0.9 by Day 10." },
    { title:"2. Immune Glomerulonephritis", color:C.gold, detail:"Hematuria + proteinuria on admission.\nCause: Circulating immune complexes.\nManagement: Resolved with antibiotics alone (no steroids).\nOutcome: Urinalysis improving by Week 3." },
    { title:"3. Splenic Embolic Infarct (Day 6)", color:"6B48B5", detail:"Left upper quadrant pain Day 6.\nCT: Small splenic infarct found.\nManagement: Analgesics ONLY – NO anticoagulation.\nReason: Risk of hemorrhagic conversion.\nOutcome: Resolved conservatively." },
  ];

  comps.forEach((c, i) => {
    const cy = 1.6 + i * 1.15;
    sl.addShape(pres.shapes.RECTANGLE, { x:0.35, y:cy, w:0.22, h:0.9, fill:{color:c.color}, line:{color:c.color} });
    sl.addText(c.title, { x:0.65, y:cy+0.03, w:7.2, h:0.32, fontSize:10.5, bold:true, color:c.color, fontFace:"Calibri", margin:0 });
    sl.addText(c.detail, { x:0.65, y:cy+0.35, w:7.2, h:0.68, fontSize:9, color:C.slate, fontFace:"Calibri", margin:0 });
  });

  // Prophylaxis
  card(sl, 8.5, 1.2, 4.5, 4.0);
  sectionLabel(sl, "ANTIBIOTIC PROPHYLAXIS", 8.5, 1.2, 4.5);
  sl.addText([
    { text:"AHA 2007 / ESC 2015 Guidelines\n\n", options:{bold:true, breakLine:true, color:C.teal} },
    { text:"Before ANY future dental procedure:\n", options:{bold:true, breakLine:true} },
    { text:"• Amoxicillin 2g orally\n  30–60 min before procedure\n\n", options:{breakLine:true} },
    { text:"If Penicillin allergic:\n", options:{bold:true, breakLine:true} },
    { text:"• Clindamycin 600 mg  OR\n• Azithromycin 500 mg\n  (oral, before procedure)\n\n", options:{breakLine:true} },
    { text:"Who needs prophylaxis?\n", options:{bold:true, breakLine:true} },
    { text:"✓ Prior history of IE ← Our patient\n✓ Prosthetic heart valves\n✓ Unrepaired cyanotic CHD\n✓ Cardiac transplant with valvulopathy", options:{} },
  ], { x:8.6, y:1.6, w:4.3, h:3.45, fontSize:9.5, color:C.navy, fontFace:"Calibri", valign:"top" });

  // Viva trap box
  card(sl, 0.3, 5.3, 12.7, 0.95, "FFF0F0");
  sl.addText("⚠  Common Viva Trap: IE + embolic infarct → Do NOT anticoagulate. AHA 2015 advises against anticoagulation in IE with embolic events (risk of hemorrhagic transformation). Only anticoagulate if there is a pre-existing firm indication (mechanical valve, AF).",
    { x:0.5, y:5.35, w:12.4, h:0.85, fontSize:10, color:C.red, fontFace:"Calibri" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 18 – PATIENT COUNSELLING, DISCHARGE & OUTCOME
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Patient Counselling, Discharge Summary & Outcome", "Slide 18 of 18");

  // Counselling
  card(sl, 0.3, 1.2, 7.0, 3.5);
  sectionLabel(sl, "PATIENT COUNSELLING POINTS", 0.3, 1.2, 7.0);
  const counselItems = [
    ["IV Therapy Compliance", "4 weeks of IV antibiotics needed – bacteria inside vegetation require prolonged killing"],
    ["Missed Doses", "Missing even 1 dose risks treatment failure → drug-resistant relapse"],
    ["Toxicity Signs", "Report: Decreased hearing, tinnitus, dizziness (ototoxicity); decreased urine output (nephrotoxicity)"],
    ["NSAIDs Warning", "Avoid NSAIDs (ibuprofen, aspirin) – increase bleeding risk from embolic sites"],
    ["Dental Hygiene", "Excellent oral hygiene; regular dental checkups reduce bacteremia risk"],
    ["Prophylaxis Card", "Carry antibiotic prophylaxis card to EVERY dental/surgical visit for LIFE"],
    ["Red Flags", "Return immediately: Recurrent fever, new neurological symptoms, chest pain, breathlessness"],
  ];
  const counselRows = [[
    { text:"Topic", options:{bold:true, fill:{color:C.teal}, color:C.white} },
    { text:"Counselling Content", options:{bold:true, fill:{color:C.teal}, color:C.white} }
  ], ...counselItems.map(r => [{ text:r[0], options:{bold:true} }, r[1]])];
  sl.addTable(counselRows, { x:0.3, y:1.55, w:7.0, h:3.1, colW:[2.1,4.9], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.4 });

  // Outcome
  card(sl, 7.6, 1.2, 5.4, 3.5);
  sectionLabel(sl, "OUTCOME AT DISCHARGE (Day 5)", 7.6, 1.2, 5.4);
  const outRows = [
    [{ text:"Parameter", options:{bold:true, fill:{color:C.green}, color:C.white} }, { text:"Value", options:{bold:true, fill:{color:C.green}, color:C.white} }],
    ["Temperature", { text:"36.8°C (Afebrile 36 hrs)", options:{color:C.green} }],
    ["BP", "108/70 mmHg – Stable"],
    ["SpO2", { text:"97% room air ✅", options:{color:C.green} }],
    ["Hb", "10.2 g/dL (improving)"],
    ["CRP", "22 mg/L (↓ from 68)"],
    ["S. Creatinine", { text:"0.9 mg/dL ✅ (baseline)", options:{color:C.green} }],
    ["Blood Culture", "Pending repeat – expected -ve"],
    ["Hearing", { text:"Intact ✅", options:{color:C.green} }],
    ["Vegetation (echo)", "Unchanged at discharge"],
  ];
  sl.addTable(outRows, { x:7.6, y:1.55, w:5.4, h:3.1, colW:[2.4,3.0], border:{pt:0.5,color:C.ltGray}, fontSize:9.5, fontFace:"Calibri", rowH:0.3 });

  // Discharge meds
  card(sl, 0.3, 4.8, 12.7, 1.0, C.ltTeal);
  sectionLabel(sl, "DISCHARGE MEDICATIONS", 0.3, 4.8, 12.7);
  sl.addText("1. Penicillin G 3 MU IV q4h → Continue OPAT (3 more weeks)     2. Furosemide 20 mg oral OD     3. Lisinopril 2.5 mg oral OD (MR afterload reduction)     4. Antibiotic Prophylaxis Card issued (Amoxicillin 2g before dental procedures)", {
    x:0.5, y:5.15, w:12.4, h:0.6, fontSize:10, color:C.navy, fontFace:"Calibri"
  });

  // Follow-up
  card(sl, 0.3, 5.85, 12.7, 0.6, "E8F0E8");
  sl.addText("Follow-up: Cardiology clinic in 2 weeks – Mitral valve repair/replacement evaluation (RHD + IE = valve damage likely to progress). Avoid strenuous activity until vegetation fully resolved.",
    { x:0.5, y:5.9, w:12.4, h:0.5, fontSize:9.5, color:C.green, fontFace:"Calibri" });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 19 – VIVA Q&A + REFERENCES
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  addSlideHeader(sl, "Examiner Viva Q&A & References", "Slide 19 of 18");

  card(sl, 0.3, 1.2, 7.8, 5.1);
  sectionLabel(sl, "EXPECTED VIVA QUESTIONS & ANSWERS", 0.3, 1.2, 7.8);

  const vivaItems = [
    { q:"Why bactericidal and not bacteriostatic therapy in IE?", a:"Vegetations are avascular – bacteria are deep inside fibrin in metabolically inactive state. Only bactericidal agents achieve sufficient killing." },
    { q:"Why Gentamicin only 2 weeks, not 4?", a:"Synergistic benefit is achieved in 2 weeks. Beyond that, irreversible ototoxicity (cochlear hair cells) and nephrotoxicity risk outweigh benefit for highly susceptible strains." },
    { q:"TTE vs TEE – when to use which?", a:"TTE first in all patients (sensitivity 50–60%). TEE (sensitivity 90%) when TTE negative but suspicion remains high, prosthetic valves, or suspected perivalvular abscess." },
    { q:"Why was anticoagulation NOT given for splenic embolus?", a:"Risk of hemorrhagic transformation of embolic infarcts. AHA 2015: avoid anticoagulation unless pre-existing indication exists (mechanical valve, AF)." },
    { q:"What is the pharmacist's specific role?", a:"Empiric regimen selection, dose calculation (IBW for Gentamicin), TDM peak/trough sampling timing & interpretation, dose adjustment, ADR surveillance, antibiotic prophylaxis counselling." },
    { q:"What is Definite IE by Duke criteria?", a:"2 Major criteria  OR  1 Major + 3 Minor criteria  OR  5 Minor criteria. Our patient: 2 Major criteria (cultures + echo vegetation) = Definite IE." },
  ];

  vivaItems.forEach((v, i) => {
    const vy = 1.6 + i * 0.78;
    sl.addText("Q" + (i+1) + ": " + v.q, { x:0.45, y:vy, w:7.5, h:0.28, fontSize:9.5, bold:true, color:C.navy, fontFace:"Calibri", margin:0 });
    sl.addText("→ " + v.a, { x:0.55, y:vy+0.28, w:7.3, h:0.43, fontSize:9, color:C.slate, fontFace:"Calibri", margin:0 });
  });

  card(sl, 8.5, 1.2, 4.5, 5.1);
  sectionLabel(sl, "REFERENCES", 8.5, 1.2, 4.5);
  const refs = [
    "1. Harrison's Principles of Internal Medicine, 22nd Ed. (2025) – Ch.63",
    "2. Fuster & Hurst's The Heart, 15th Ed. – Ch.33, Tables 33-4, 33-9",
    "3. Washington Manual of Medical Therapeutics – Ch.14, Tables 14-5,6,7",
    "4. Goldman-Cecil Medicine – Ch.61",
    "5. Baddour LM et al. AHA Scientific Statement. Circulation. 2015;132(15):1435-1486.",
    "6. Habib G et al. ESC Guidelines for IE. Eur Heart J. 2015;36(44):3075.",
    "7. Dipiro JT et al. Pharmacotherapy: A Pathophysiologic Approach, 11th Ed. – Ch.104",
    "8. Li JS et al. Duke Criteria Modifications. Clin Infect Dis. 2000;30(4):633.",
  ];
  refs.forEach((r, i) => {
    sl.addText(r, { x:8.6, y:1.6 + i*0.56, w:4.3, h:0.5, fontSize:8.5, color:C.slate, fontFace:"Calibri", valign:"top" });
  });
}

// ═══════════════════════════════════════════════════════════════════════════
// SLIDE 20 – CLOSING SLIDE
// ═══════════════════════════════════════════════════════════════════════════
{
  let sl = pres.addSlide();
  sl.background = { color: C.navy };
  sl.addShape(pres.shapes.RECTANGLE, { x:0, y:0, w:0.35, h:7.5, fill:{color:C.teal}, line:{color:C.teal} });
  sl.addShape(pres.shapes.RECTANGLE, { x:0.35, y:3.4, w:12.95, h:0.06, fill:{color:C.gold}, line:{color:C.gold} });

  sl.addText("Thank You", { x:0.6, y:1.5, w:12, h:1.2, fontSize:52, bold:true, color:C.white, align:"center", fontFace:"Calibri" });
  sl.addText("Native Valve Infective Endocarditis – S. viridans", { x:0.6, y:2.7, w:12, h:0.55, fontSize:16, color:"7EC8E3", align:"center", fontFace:"Calibri", italic:true });

  sl.addText([
    { text:"Open for Questions", options:{bold:true, color:C.gold} },
  ], { x:0.6, y:3.7, w:12, h:0.6, fontSize:18, align:"center", fontFace:"Calibri" });

  sl.addText("Pharmacotherapeutics – II  |  3rd Year PharmD", { x:0.6, y:5.5, w:12, h:0.4, fontSize:12, color:C.midGray, align:"center", fontFace:"Calibri" });
  sl.addText("References: Harrison's 22E · Fuster & Hurst 15E · Washington Manual · AHA 2015 · ESC 2015", {
    x:0.6, y:6.1, w:12, h:0.35, fontSize:9, color:"506070", align:"center", fontFace:"Calibri"
  });
}

// ── WRITE FILE ───────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/ie-case-presentation/IE_NativeValve_PharmD_CasePresentation.pptx" })
  .then(() => { console.log("✅ PPTX created successfully"); })
  .catch(e => { console.error("❌ Error:", e); });

Running Command

cd /home/daytona/workspace/ie-case-presentation && node build.js 2>&1

Running Command

ls -lh /home/daytona/workspace/ie-case-presentation/

Your PowerPoint is ready - 1.1 MB, 20 slides, fully formatted.

IE NativeValve PharmD CasePresentation

Presentation · PPTX

What's inside (20 slides):

Slide	Content
1	Title slide - navy/teal theme with heart symbol
2	Patient profile + chief complaints (dual card layout)
3	Clinical signs - vascular vs immunologic phenomena (color-coded)
4	Investigations - labs + blood culture + sensitivity profile + echo
5	Duke Criteria - verdict banner + major/minor criteria tables
6	Pathophysiology flowchart + 3 consequence boxes
7	Treatment goals - 6 numbered goal cards
8	Drug 1: Vancomycin (empiric, Days 1-2)
9	Drug 2: Penicillin G (definitive, Day 3 onwards)
10	Drug 3: Gentamicin (synergy + toxicity)
11	TDM - Gentamicin targets + Day 5 dose adjustment scenario
12	Drugs 4 & 5: Furosemide + Paracetamol
13	5-Day Master Timeline - all drugs, all events in one table
14	Drug Interactions table + TDM Quick Reference Card
15	5 Drugs at a Glance - revision card with colored strips
16	Monitoring parameters (clinical + lab + ototoxicity)
17	Complications + Antibiotic Prophylaxis guidelines
18	Patient counselling + Discharge summary + Outcome
19	Viva Q&A (6 questions with answers) + References
20	Closing thank-you slide

Color theme: Navy + Teal + Gold - professional, exam-ready, visually distinct from plain white presentations.

Can u suggest me a best title catchy yet innovative n simple

Here are title options ranked from boldest to most formal — pick what matches your style:

🏆 Top Pick

"When the Heart Harbours the Enemy"

A Case of Native Valve Infective Endocarditis due to Streptococcus viridans

Why it works: Instantly creates intrigue. "Enemy" = the bacteria living inside the vegetation on the valve. Poetic, memorable, and examiners will remember it. The subtitle grounds it clinically.

Strong Alternatives

🥈 "The Silent Invader"

Subacute Bacterial Endocarditis — From Dental Chair to Damaged Valve

Why it works: Tells the whole story in the subtitle. "Silent" = classic SBE insidious onset. Very easy to build your opening narrative around.

🥉 "A Tooth, a Bacterium, and a Broken Valve"

Pharmacotherapy of Native Valve IE due to Streptococcus viridans

Why it works: Simple, human, story-driven. Every examiner immediately understands the mechanism (dental → bacteremia → valve). Unusual enough to stand out.

Other Good Options

Title	Tone
"Bacteria Behind the Beat"	Catchy, modern
"The Vegetation Dilemma"	Clinical, confident
"From Mouth to Mitral"	Concise, story-driven
"Viridans at the Gate"	Bold, metaphorical
"A Case Where Bugs and Drugs Collide"	Informal, fun — risky but memorable
"The 4-Week Battle Inside the Heart"	Action-oriented, duration-focused

For a Formal Exam Context (Safe + Smart)

"From Bacteremia to Vegetation: A Pharmacotherapeutic Journey in Native Valve Infective Endocarditis"

Use this if your college prefers traditional academic titles. Still more interesting than the plain version but respects formal presentation norms.

My final recommendation: Go with "When the Heart Harbours the Enemy" as your main title with the clinical subtitle below it. It is the kind of title that makes the examiner look up from their paper before you even start speaking - which is exactly the impression you want.

Is there any past medication history,family ,social n allergic history to be added for specific

Great question - these histories are actually HIGH-YIELD in IE because each one directly influences drug choice, dosing, or risk. Here is exactly what to add and WHY each point matters clinically:

📋 COMPLETE HISTORY – What to Add (IE-Specific)

1. PAST MEDICATION HISTORY

Medication	Duration	Clinical Relevance to IE
Benzathine Penicillin G 1.2 MU IM monthly	Since age 14 (RHD prophylaxis)	Critical - Patient was on long-term penicillin prophylaxis for RHD. Examiner will ask: "Did prophylaxis fail?" Answer: Yes - S. viridans can develop relative penicillin tolerance with prolonged prophylaxis exposure
Amoxicillin 500 mg TID × 5 days	2 weeks before admission	Partial treatment from local clinic - explains why blood cultures may be harder to grow; all 3 sets still positive (organism not fully suppressed)
No prior aminoglycosides	—	Baseline ototoxicity risk = low - safe to start Gentamicin TDM. If patient had prior aminoglycoside use, risk would be significantly higher
No prior NSAIDs or nephrotoxic drugs	—	Baseline renal function preserved (SCr 0.9) - confirms Gentamicin is safe to initiate

Examiner Gold: "Patient was on monthly Benzathine Penicillin for RHD prophylaxis yet still developed IE. Why?" — Answer: Prophylaxis prevents RHD progression, not IE. IE prophylaxis requires a different strategy (pre-dental Amoxicillin 2g), which was never given before his tooth extraction.

2. FAMILY HISTORY

Finding	Relevance
Father had Rheumatic Heart Disease	Suggests genetic susceptibility to rheumatic fever + RHD — important for counselling siblings/children
No family history of IE	IE itself is not hereditary, but predisposing structural heart disease can run in families
No family history of hearing loss	Rules out pre-existing familial ototoxicity susceptibility before starting Gentamicin
No family history of G6PD deficiency	Relevant if alternative drugs like Dapsone or certain antibiotics were considered

Why it matters for the examiner: Family history of RHD explains why the patient had pre-existing valve damage (the entry point for IE). Without damaged endothelium, S. viridans bacteremia rarely causes IE in healthy valves.

3. SOCIAL HISTORY

Factor	Finding	Clinical Relevance
IV drug use	ABSENT	Important negative - IV drug users get right-sided IE (tricuspid valve), S. aureus is organism. Our patient has LEFT-sided (mitral) IE with S. viridans = confirms community-acquired, dental source
Occupation	Office employee	Sedentary work - relevant for OPAT compliance (can continue IV antibiotics at home without physical exertion issues)
Alcohol use	Occasional (social)	Moderate use - caution with Paracetamol (max 2g/day in regular drinkers vs 4g/day normally). Also affects immune function
Smoking	Non-smoker	No additional cardiopulmonary compromise
Dental hygiene	Poor (irregular dental visits, no dentist for 3 years before the extraction)	Direct cause - poor oral hygiene = higher oral bacterial load = higher bacteremia risk during dental procedures
Living situation	Lives with family	Supports OPAT plan - family can assist with IV care at home after discharge
Recent travel	None	Rules out exotic infections (Brucella, Q fever, Bartonella) as culture-negative IE causes

Examiner Gold: "Why did this patient get IE when many people have dental extractions without issue?" — Answer: Pre-existing damaged valve (RHD) + high oral bacterial load (poor hygiene) + no prophylactic antibiotic before extraction = perfect storm for S. viridans seeding.

4. ALLERGIC HISTORY

Allergen	Status	Why This is Critical
Penicillin	No known allergy ✅	THE most important allergy to rule out in IE. Penicillin G is first-line for S. viridans. If allergic → must switch to Ceftriaxone (mild allergy) or Vancomycin (anaphylaxis history)
Cephalosporins	No allergy ✅	Backup option (Ceftriaxone 2g OD) confirmed safe if needed
Sulfonamides	No allergy ✅	Relevant for Cotrimoxazole if co-infections considered
Contrast dye / Iodine	No allergy ✅	Relevant if CT angiography needed for embolic complications
Latex	No allergy ✅	Relevant for IV line insertion / surgical gloves

The Allergy Tree for IE Treatment:

Penicillin allergy?
    │
    ├── NO → Penicillin G 18 MU/day × 4 weeks (FIRST LINE) ✅
    │
    ├── YES (mild/moderate rash) → Ceftriaxone 2g OD × 4 weeks
    │
    └── YES (anaphylaxis/urticaria) → Vancomycin 30 mg/kg/day × 4 weeks
                                       (NO Gentamicin needed for Strep)

Summary: How to Present These in Your Case

Add them as a single structured slide right after Chief Complaints:

SLIDE: DETAILED HISTORY

Past Medication History:

Benzathine Penicillin G 1.2 MU IM monthly (RHD prophylaxis since age 14) - prophylaxis for RHD, NOT for IE
Amoxicillin 500 mg TID × 5 days (local clinic, 2 weeks prior) - partial pre-treatment

Family History:

Father: Rheumatic Heart Disease (explains structural predisposition)
No family history of IE, hearing loss, or G6PD deficiency

Social History:

No IV drug use (confirms left-sided, community-acquired IE)
Poor dental hygiene (no dentist visit for 3 years)
Occasional alcohol (Paracetamol dose = max 2g/day)
Non-smoker, lives with family (supports OPAT compliance)

Allergic History:

Penicillin: No known allergy ✅ (confirms Penicillin G first-line safe)
No allergy to Cephalosporins, Sulfonamides, Contrast, Latex

These details do two things for your marks:

They show the examiner you understand that every history point has a pharmacotherapy consequence
They demonstrate clinical reasoning - not just knowing the drugs, but knowing WHY each drug is safe or appropriate for THIS specific patient

Possible provisional diagnosis

Excellent question - this is what separates a topper from an average presenter. You must show the examiner that you thought through multiple diagnoses BEFORE the investigations confirmed IE.

PROVISIONAL DIAGNOSIS FRAMEWORK

Clinical situation at admission (Day 1, before any results): 42M, RHD background, dental extraction 6 weeks ago, 3 weeks of low-grade fever + fatigue + arthralgias + mild breathlessness + new murmur character change + splinter hemorrhages + Osler nodes + Roth spots

PRIMARY PROVISIONAL DIAGNOSIS

Subacute Bacterial Endocarditis (SBE) - Native Valve, most likely Mitral

Basis for this provisional diagnosis (before investigations):

Clinical Clue	Points Toward SBE
Known RHD + mitral regurgitation	Pre-existing damaged valve = entry point
Dental extraction 6 weeks ago (no prophylaxis)	Classic precipitating bacteremia event
3 weeks insidious low-grade fever	SBE pattern (vs ABE which is acute days)
Fatigue + night sweats + weight loss	Classic constitutional symptoms
Splinter hemorrhages + Janeway lesions	Embolic/vascular phenomena
Osler nodes + Roth spots	Immune complex phenomena
Pansystolic murmur (possibly changed)	Valvular involvement
Splenomegaly	Chronic bacteremia
Weakly positive RF	Immune activation

Key teaching point: You can provisionally diagnose SBE purely on clinical grounds before any blood culture or echo result. The combination of fever + new murmur + embolic signs + predisposing condition is enough to START empiric therapy.

DIFFERENTIAL DIAGNOSES (Ranked by Likelihood)

DD 1 - Acute Rheumatic Fever (ARF) Reactivation 🔴 High priority to rule out

Feature	Supports ARF	Against ARF
RHD background	✅
Fever	✅
Migratory arthralgia	✅
Recent Strep infection?	Need to ask	No recent sore throat reported
Carditis / murmur change	✅
Splinter hemorrhages, Osler nodes	❌ Not seen in ARF
ASO titre elevated?	Need to check

How to rule out: ASO titre + throat swab + ECHO (ARF shows pancarditis, not vegetation) Why important: Treatment differs completely - ARF = Penicillin + anti-inflammatory (NSAIDs/steroids). IE = prolonged bactericidal IV therapy. Confusing them is dangerous.

DD 2 - Systemic Lupus Erythematosus (SLE) with Libman-Sacks Endocarditis 🟡 Moderate priority

Feature	Supports SLE	Against SLE
Young patient	✅
Fever + arthralgia	✅
Roth spots	✅
Renal involvement (hematuria, proteinuria)	✅
Positive RF	✅ (low titre)
Vegetation on echo	✅ (Libman-Sacks)	SLE vegetations are sterile, small, on both surfaces
Positive blood cultures	❌ Not in SLE	Our patient has positive cultures
Gender	More common in females	Our patient is male

How to rule out: ANA, anti-dsDNA, complement C3/C4, CBC for cytopenia Key differentiator: Libman-Sacks endocarditis = STERILE vegetations. Blood cultures will be negative. Our patient had positive cultures = rules out SLE as primary diagnosis.

DD 3 - Viral Endocarditis / Culture-Negative IE 🟡 Consider if cultures negative

Feature	Details
Organisms	Coxiella burnetii (Q fever), Bartonella, Brucella, Tropheryma whipplei
Clinical overlap	All present like SBE - fever, fatigue, valve involvement
How to differentiate	Blood cultures negative × 3 sets + serology for above organisms
Relevance here	Ruled out because ALL 3 blood cultures were positive for S. viridans

DD 4 - Rheumatoid Arthritis with Systemic Features 🟢 Lower priority

Feature	Supports RA	Against RA
Migratory arthralgia	✅
Weakly positive RF	✅
Fatigue + malaise	✅
Fever	✅ (low-grade)
Splinter hemorrhages	❌ Not typical in RA
Blood cultures	❌ Not positive in RA
Echo vegetation	❌ Not a feature of RA

Essentially excluded by positive blood cultures + echocardiographic vegetation.

DD 5 - Malaria / Chronic Parasitic Infection 🟢 Low priority (rule out)

Feature	Notes
Fever + splenomegaly	Common to both
Fatigue, night sweats	Common to both
How to rule out	Peripheral blood smear + RDT for malaria antigen
Relevance	No travel history, no mosquito exposure history reported → low likelihood

PROVISIONAL DIAGNOSIS STATEMENT (Write exactly like this in your case)

"Based on the history of predisposing rheumatic heart disease, preceding dental extraction without antibiotic prophylaxis, 3-week history of insidious low-grade fever with constitutional symptoms, presence of peripheral vascular and immunologic phenomena (splinter hemorrhages, Osler nodes, Roth spots, Janeway lesions), and a changing cardiac murmur — the provisional diagnosis is:

Subacute Bacterial Endocarditis (SBE) of the Native Mitral Valve, most likely due to Viridans group Streptococci, pending confirmation by blood cultures and echocardiography.

Differentials considered: Acute Rheumatic Fever reactivation, SLE with Libman-Sacks endocarditis, Culture-negative IE."

Then on the NEXT slide — Confirmed Diagnosis

"Following blood cultures (positive S. viridans × 3 sets) and TEE (8mm oscillating vegetation, mitral posterior leaflet) — the diagnosis is confirmed as DEFINITE Native Valve Infective Endocarditis by Modified Duke Criteria (2 Major criteria met)."

How This Earns You Extra Marks

What you show	Marks Impact
You listed DDs BEFORE investigations	Clinical reasoning = examiner impressed
You distinguished SBE from ABE clinically	Shows depth
You included ARF as DD and explained why it matters	Most students miss this
You cited SLE Libman-Sacks specifically	Rare knowledge - stands out
Your provisional statement is structured and confident	Professionalism
You moved cleanly from provisional → confirmed diagnosis	Logical case flow

The provisional → confirmed diagnosis arc is the clinical thinking backbone of your entire presentation. It shows you are not just memorising drug doses - you are reasoning like a clinical pharmacist.

Wt is the cvs,rs,cns,pa systemic examination

Here is the complete, detailed systemic examination for your IE case - exactly as it would be documented in a real case record and presented in an exam.

SYSTEMIC EXAMINATION

1. CVS - CARDIOVASCULAR SYSTEM EXAMINATION

Inspection

Finding	Result
Precordial bulge	Absent
Visible pulsations	Apex beat visible in 5th ICS, MCL
Dilated veins over chest	Absent
Surgical scars	Absent

Palpation

Finding	Result	Significance
Apex beat	5th ICS, midclavicular line	Normal position (no cardiomegaly yet)
Character of apex	Heaving (hyperdynamic)	Suggests volume overload from mitral regurgitation
Parasternal heave	Absent	No RV enlargement
Thrills	No palpable thrill	Grade III murmur - below thrill threshold
JVP	Mildly elevated - 5 cm above sternal angle	Early right heart pressure elevation

Percussion

Finding	Result
Cardiac dullness	Within normal limits
No significant cardiac enlargement	Confirmed

Auscultation - THE MOST IMPORTANT PART ⭐

Component	Finding	Significance
S1	Soft/diminished at mitral area	Mitral regurgitation - valve doesn't close properly
S2	Normal, well heard at aortic and pulmonary areas	No aortic involvement
Murmur	Pansystolic (holosystolic) Grade III/VI at apex	Mitral regurgitation from leaflet damage by vegetation
Radiation	Radiates to left axilla	Classic radiation of MR murmur
S3 gallop	Present (faint)	Early sign of volume overload / impending heart failure
S4	Absent	No LV stiffness / diastolic dysfunction
Pericardial rub	Absent	No pericarditis
Additional sounds	No clicks, no opening snap	Rules out MS as dominant lesion

Murmur Grading Reminder:

Grade I: Barely audible

Grade II: Soft but easily heard

Grade III: Moderately loud, no thrill ← Our patient

Grade IV: Loud with thrill

Grade V: Heard with stethoscope barely on chest

Grade VI: Heard without stethoscope

Examiner point: The murmur in SBE due to S. viridans on mitral valve is typically pansystolic (MR). If the murmur was early diastolic (AR), it would suggest aortic valve involvement - a far more dangerous location. Always specify murmur type, grade, and radiation.

2. RS - RESPIRATORY SYSTEM EXAMINATION

Inspection

Finding	Result	Significance
Shape of chest	Normal, symmetric	No deformity
Respiratory rate	20/min (mildly elevated)	Mild tachypnea - early pulmonary congestion
Type of breathing	Thoraco-abdominal	Normal
Use of accessory muscles	Absent	No severe distress
Intercostal retractions	Absent
Trachea	Central	Not deviated

Palpation

Finding	Result
Tracheal position	Central
Chest expansion	Bilaterally equal, slightly reduced at bases
Vocal fremitus	Slightly increased bilateral bases

Percussion

Area	Finding	Significance
Upper zones (bilateral)	Resonant	Normal air-filled lung
Lower zones (bilateral bases)	Dull	Fluid in bases - early pulmonary edema from MR
Liver dullness	Normal upper border at 5th ICS	No hyperinflation

Auscultation

Finding	Result	Significance
Air entry	Vesicular, present bilaterally
Bilateral basal crepitations (fine)	Present	Pulmonary congestion - fluid from raised LVEDP due to MR
Wheeze	Absent	No bronchospasm
Pleural rub	Absent	No pleuritis
Bronchial breath sounds	Absent	No consolidation
SpO2	96% on room air	Mild reduction from pulmonary congestion

Why RS findings matter pharmacologically: Bilateral basal crepitations + mild dullness at bases = early pulmonary congestion = justification for adding Furosemide (Drug 4) on Day 3. This is your clinical evidence for that drug decision.

3. CNS - CENTRAL NERVOUS SYSTEM EXAMINATION

Why CNS exam is critical in IE: IE can embolise to the brain → stroke, cerebral abscess, mycotic aneurysm. CNS complications occur in 15-20% of IE cases and are the most feared complication.

Higher Functions

Parameter	Finding
Consciousness	Alert and oriented to time, place, person
Speech	Normal, fluent
Memory	Intact
Mood	Anxious (appropriate to illness)

Cranial Nerves

Nerve	Finding	Significance
CN II (Optic)	Roth spots on fundoscopy bilateral	Immune complex vasculitis in retinal vessels
CN II - Visual acuity	Normal	No embolic retinal artery occlusion
CN III, IV, VI	EOM full, no diplopia	No cranial nerve palsy
CN VII	No facial asymmetry	No cerebral embolism
CN VIII (Vestibulocochlear)	Hearing intact bilaterally (baseline)	Documented BEFORE Gentamicin - critical for TDM
CN IX, X	Gag reflex intact, palate moves symmetrically
CN XII	Tongue midline	No hypoglossal palsy

Motor System

Finding	Result
Tone	Normal in all 4 limbs
Power	5/5 bilaterally
Deep tendon reflexes	++/++ (normal) bilaterally
Plantar response	Flexor bilaterally (normal)

Sensory System

Finding	Result
Pain, temperature, touch	Intact
Vibration and proprioception	Intact

Cerebellar Signs

Finding	Result
Finger-nose test	Normal
Gait	Normal, no ataxia
Romberg's sign	Negative

Examiner point: Documenting CN VIII (hearing) as intact BEFORE starting Gentamicin is a mandatory pharmacist responsibility. If ototoxicity develops during therapy, this baseline allows attribution. If you don't document baseline hearing, you cannot prove whether hearing loss was pre-existing or drug-induced.

4. PA - PER ABDOMEN (Abdominal) EXAMINATION

Inspection

Finding	Result
Shape	Flat, no distension
Umbilicus	Central, inverted
Visible peristalsis	Absent
Dilated veins	Absent
Surgical scars	Absent

Palpation

Organ	Finding	Significance
Abdomen (general)	Soft, non-tender	No peritonism
Liver	Not enlarged, smooth border	No hepatomegaly (no right heart failure yet)
Spleen	Palpable 2 cm below left costal margin, smooth, non-tender	Splenomegaly - classic finding in SBE from chronic bacteremia + immune activation
Kidneys	Not palpable	Normal
Left hypochondrium (Day 6 onwards)	Mild tenderness	Splenic infarct (embolic complication discovered Day 6)

Percussion

Finding	Result
Liver span	Normal (12 cm)
Splenic dullness	Present in left lateral area - confirms splenomegaly
Ascites (shifting dullness)	Absent
Fluid thrill	Absent

Auscultation

Finding	Result
Bowel sounds	Present, normal (3-4/min)
Splenic rub	Absent on admission (heard Day 6 if splenic infarct is large)
Renal bruit	Absent

Hernial Orifices & Genitalia

Finding	Result
Hernial orifices	No hernia
External genitalia	Normal

COMPLETE SYSTEMIC EXAMINATION SUMMARY TABLE

System	Key Positive Findings	Pharmacotherapy Link
CVS	Pansystolic murmur Gr III/VI at apex → axilla; Soft S1; Faint S3; Mild JVP elevation; Heaving apex	Confirms MR from mitral valve vegetation; justifies Lisinopril at discharge
RS	Fine bibasal crepitations; Dull at bases; RR 20/min; SpO2 96%	Pulmonary congestion from MR → justifies Furosemide Day 3
CNS	Alert and oriented; Roth spots on fundoscopy; CN VIII intact (baseline hearing documented)	No cerebral embolism; Baseline hearing = mandatory pre-Gentamicin documentation
PA	Splenomegaly 2 cm; Day 6 - left hypochondrial tenderness	Splenomegaly = chronic bacteremia marker; Day 6 tenderness = splenic infarct → No anticoagulation

How to Present This in Your Case (Examiner Tips)

Always start CVS with auscultation findings in IE - that is where the disease lives
Mention the murmur grade, type, and radiation - all three, every time
RS findings directly justify Furosemide - make this link explicit
Documenting baseline CN VIII shows you are thinking like a clinical pharmacist, not just a doctor
Splenic tenderness on Day 6 sets up your complication discussion (splenic infarct) and the anticoagulation decision
Connect every positive finding back to IE pathophysiology - vegetation → valve damage → MR → pulmonary congestion → bibasal crepitations → Furosemide

This is the full, exam-ready systemic examination. Every finding has a reason, and every reason connects back to a drug decision.

Pickle examination

You likely mean "Physical Examination" - the general head-to-toe examination done before the systemic examination. Here is the complete one for your IE case:

PHYSICAL EXAMINATION (General Examination)

PART A - GENERAL APPEARANCE

Parameter	Finding	Significance
General condition	Moderately ill-looking, conscious, cooperative	SBE - not acutely toxic (unlike ABE)
Built and nourishment	Average built, mild weight loss noted	Chronic infection causing catabolism
Posture	Comfortable, no orthopnea at rest	No severe HF yet
Pallor	Present (mild to moderate) - conjunctival pallor	Anemia of chronic infection (Hb 9.8)
Cyanosis	Absent - peripherally and centrally	No right-to-left shunt, no severe hypoxia
Icterus (Jaundice)	Absent	No hepatic involvement, no hemolysis
Clubbing	Absent (important negative in acute IE)	Clubbing seen only in longstanding chronic IE (>6 weeks)
Lymphadenopathy	Mild cervical lymphadenopathy	Immune activation from chronic bacteremia
Edema	Mild bilateral pedal edema (1+, pitting)	Early congestive features from MR

Examiner Trap: Clubbing is classically associated with IE in textbooks - but it takes 6-12 weeks of active infection to develop. Our patient has 3-week history, so clubbing is ABSENT. If you say clubbing is present, the examiner will question your timeline.

PART B - VITAL SIGNS

Parameter	Value	Normal Range	Interpretation
Temperature	38.4°C (Febrile)	36.1–37.2°C	Low-grade fever - SBE pattern
Pulse rate	96/min	60–100/min	Upper normal - mild tachycardia from fever
Pulse character	Regular rhythm, normal volume		No irregularity (no AF at this stage)
Pulse - all peripheral pulses	Present and equal bilaterally		No embolic arterial occlusion
Blood Pressure	110/70 mmHg	120/80 mmHg	Mildly low - suggests early reduced cardiac output
BP in both arms	Equal		Rules out aortic dissection
Respiratory Rate	20/min	12–18/min	Mildly elevated - early pulmonary congestion
SpO2	96% on room air	98–100%	Mildly reduced - pulmonary congestion
Weight	65 kg		Used for drug dose calculations (Gentamicin, Vancomycin)
Height	168 cm		IBW calculation for Gentamicin
BMI	23 kg/m²	18.5–24.9	Normal

PART C - HANDS AND UPPER LIMBS (High Yield in IE)

Finding	Result	Significance
Splinter hemorrhages	Present - 3–4 fingers bilaterally, subungual, linear, dark red	Vascular phenomenon - microemboli in nail bed vessels
Osler nodes	Present - tender raised nodules on fingertip pulp (index + middle fingers bilateral)	Immunologic phenomenon - immune complex deposition
Janeway lesions (palms)	Present - non-tender erythematous irregular macules on thenar and hypothenar eminence	Embolic/vascular phenomenon
Clubbing	Absent (as discussed above)	Disease duration < 6 weeks
Peripheral cyanosis	Absent
Koilonychia	Absent
Leukonychia	Absent
Capillary refill time	< 2 seconds	Normal perfusion
Temperature of hands	Warm	No peripheral vascular compromise
Tremor	Absent	No cerebellar or toxic encephalopathy
Needle track marks	Absent	Rules out IV drug use (important negative)

How to describe Splinter hemorrhages to examiner: "Subungual, longitudinal, linear reddish-brown streaks seen in the distal third of the nail bed of 3 fingers on the right hand and 2 fingers on the left hand - consistent with vascular embolic phenomena of infective endocarditis."

PART D - EYES

Finding	Result	Significance
Conjunctival pallor	Bilateral mild pallor	Anemia (Hb 9.8 g/dL)
Scleral icterus	Absent	No jaundice
Petechiae on palpebral conjunctiva	Present (small, 2–3 spots)	Vascular embolic phenomenon
Roth spots (fundoscopy)	Bilateral - flame-shaped hemorrhages with white fibrin centers	Immunologic/embolic - pathognomonic of IE
Cornea	Clear, no arcus senilis
Pupils	Equal, round, reactive to light (PEARL)	Normal CNS perfusion

Roth spots in detail: Oval hemorrhagic retinal lesions with a white or pale center. White center = fibrin/platelet plug or immune complex. Found in IE, but also in severe anemia, leukemia, and HIV - not absolutely pathognomonic but highly suggestive in IE context.

PART E - FACE, MOUTH & ORAL CAVITY

Finding	Result	Significance
Facial expression	Anxious, mildly distressed
Dental caries	Multiple dental caries noted	Primary source of S. viridans bacteremia
Gum condition	Mild gingivitis	Additional oral bacterial reservoir
Oral hygiene	Poor	Confirms high oral flora load pre-extraction
Oral mucosa	Mild pallor	Anemia
Petechiae on soft palate	Present (2–3 spots)	Vascular embolic phenomenon
Tongue	Normal, moist
Tonsils	No active tonsillitis

Examiner point: The oral cavity examination in IE is not just a formality. Poor oral hygiene + dental caries + gingivitis = high oral S. viridans burden = higher risk of significant bacteremia during extraction. This directly explains why this patient got IE.

PART F - NECK

Finding	Result	Significance
JVP	Raised - 5 cm above sternal angle at 45°	Mild venous pressure elevation from early HF
JVP waveform	Prominent 'v' wave	Tricuspid regurgitation component OR elevated LAP transmitted
Trachea	Central	No mediastinal shift
Carotid pulse	Normal volume, no bruit	No carotid embolic occlusion
Lymph nodes	Mild submandibular + anterior cervical lymphadenopathy (soft, mobile, non-tender)	Reactive to chronic bacteremia
Neck rigidity	Absent	No meningitis
Kernig's sign	Negative	No meningeal irritation

PART G - LOWER LIMBS

Finding	Result	Significance
Pedal edema	1+ pitting, bilateral, below ankles	Early congestive heart failure from MR
Janeway lesions	Non-tender, erythematous macules - soles of both feet	Vascular embolic phenomenon
Peripheral pulses	Present and equal - dorsalis pedis + posterior tibial	No embolic arterial occlusion in lower limbs
Varicose veins	Absent
Calf tenderness	Absent	No DVT
Skin temperature	Warm	Normal perfusion

COMPLETE PHYSICAL EXAMINATION SUMMARY

Positive Findings at a Glance

Category	Finding	IE Link
Fever	38.4°C	Active infection - minor Duke criterion
Pallor	Mild-moderate	Anemia of chronic infection
Pedal edema	1+ bilateral	Early HF from MR
Splinter hemorrhages	3–4 fingers bilateral	Vascular phenomenon - Duke minor
Osler nodes	Fingertips bilateral	Immunologic phenomenon - Duke minor
Janeway lesions	Palms + soles	Vascular phenomenon - Duke minor
Petechiae	Conjunctiva + soft palate	Vascular phenomenon
Roth spots	Fundoscopy bilateral	Immunologic/embolic
Poor oral hygiene + caries	Multiple caries, gingivitis	Source of bacteremia
JVP raised	5 cm above sternal angle	Early right heart pressure
No clubbing	Absent	Confirms < 6 weeks duration
No IV needle marks	Absent	Rules out IVDU-associated IE

How to Present in Exam (Opening Statement Formula)

"On general physical examination, the patient was a moderately ill-looking, average-built male, conscious and cooperative. He was febrile (38.4°C), afebrile at rest on Day 3. Pallor was present. Cyanosis, icterus, clubbing, and generalized lymphadenopathy were absent. Bilateral lower limb pitting pedal edema (1+) was noted.

Peripheral stigmata of infective endocarditis were present - including splinter hemorrhages under the nails of both hands, Osler nodes on the fingertip pulps, and Janeway lesions over the palms and soles. Petechiae were noted on the palpebral conjunctiva and soft palate. Fundoscopic examination revealed bilateral Roth spots.

JVP was mildly elevated at 5 cm above the sternal angle. Oral hygiene was poor with multiple dental caries - consistent with the suspected portal of entry."

This physical examination, delivered in this order and linked to IE pathophysiology, is what turns a good presentation into a great one. Every finding you mention should be explainable - and in this case, every single sign connects directly back to the vegetation on the mitral valve.

This is a shared conversation. Sign in to Orris to start your own chat.

🎯 Top Case Topic Recommendation: Septicemia (Sepsis) with Multi-Drug Resistant Organisms

Strategic Analysis: Why Sepsis Wins

Scoring Criteria Assessment

The Ideal Case Title

Why NOT the "Common" Choices (Important)

Full Structured Case Presentation Framework (Topper Style)

Section 1 - Patient Profile (5 min)

Section 2 - Pathophysiology (5 min)

Section 3 - Pharmacotherapy (THE CORE - 15 min)

Section 4 - Monitoring Parameters (5 min)

Section 5 - Patient Counseling (3 min)

Section 6 - Pharmacoeconomics (Bonus marks)

Second Best Option (Backup): Infective Endocarditis

Third Option: Drug-Induced Renal Disorders (Nephrotoxicity)

Final Recommendation Summary

🏆 Final Recommendation: Tuberculosis (TB)

Why TB is the Highest-Scoring Pick for YOUR Exam

1. It covers the MOST examinable pharmacotherapy concepts in one case:

2. The "Topper Differentiator" - Make It a COMPLEX TB Case

3 High-Impact Case Title Options (Pick One)

🥇 Option A - TB + HIV Co-infection (Strongest Pick)

🥈 Option B - Drug-Resistant TB (MDR-TB)

🥉 Option C - TB Meningitis

Recommended Slide Structure (Topper Format)

Final Decision Table

📋 CASE PRESENTATION

Pharmacotherapy of Native Valve Infective Endocarditis due to Streptococcus viridans

Duke Criteria | Prolonged Bactericidal Therapy | Aminoglycoside TDM

SLIDE 1 - PATIENT PROFILE

SLIDE 2 - CHIEF COMPLAINTS

SLIDE 3 - HISTORY

Past Medical History

History of Presenting Illness

Social History

Family History

SLIDE 4 - PHYSICAL EXAMINATION

SLIDE 5 - INVESTIGATIONS

Hematology & Chemistry

Microbiology - THE MOST CRITICAL INVESTIGATION

Echocardiography (TTE first, then TEE)

SLIDE 6 - DIAGNOSIS USING MODIFIED DUKE CRITERIA

Major Criteria (2 required for Definite IE)

Minor Criteria

Duke Classification: DEFINITE INFECTIVE ENDOCARDITIS

SLIDE 7 - PATHOPHYSIOLOGY (Brief - 1 Slide)

SLIDE 8 - TREATMENT GOALS

SLIDE 9 - PHARMACOTHERAPY: EMPIRIC THERAPY (Day 1-3, before culture report)

SLIDE 10 - PHARMACOTHERAPY: DEFINITIVE THERAPY (After culture + MIC report)

Organism: Streptococcus viridans | MIC for Penicillin: 0.08 µg/mL (≤ 0.12 µg/mL) = Highly Susceptible

Chosen Regimen: Penicillin G + Gentamicin (2-week combination followed by Penicillin G alone)

Why Combination (Penicillin + Gentamicin)?

Alternatives (when Penicillin not available or allergic):

SLIDE 11 - THERAPEUTIC DRUG MONITORING (TDM) - THE PHARMACIST'S ROLE ⭐

A. Gentamicin TDM (CORE PharmD Content)

B. Vancomycin TDM (Empiric phase Days 1-3)

SLIDE 12 - MONITORING PARAMETERS (Full Chart)

Clinical Monitoring

Laboratory Monitoring

Ototoxicity Monitoring (Gentamicin-specific)

SLIDE 13 - DISEASE COURSE / PATIENT PROGRESS

SLIDE 14 - COMPLICATIONS ENCOUNTERED

1. Possible Early Nephrotoxicity (Day 5)

2. Immune Complex Glomerulonephritis

3. Embolic Splenic Infarct (Day 6 - incidental finding on CT)

SLIDE 15 - ANTIBIOTIC PROPHYLAXIS (Prevention - PharmD Role)

SLIDE 16 - PATIENT COUNSELLING

SLIDE 17 - OUTCOME & DISCHARGE SUMMARY

SLIDE 18 - REFERENCES

EXAMINER VIVA PREPARATION - Expected Questions & Answers

📋 COMPILED CASE PRESENTATION

Native Valve Infective Endocarditis - Streptococcus viridans

5-Day Hospital Stay | 5 Key Drugs | Clean & Exam-Ready

PATIENT SNAPSHOT

CHIEF COMPLAINTS

CLINICAL SIGNS (on Examination)

INVESTIGATIONS SUMMARY

DUKE CRITERIA - DEFINITE IE ✅

💊 DRUG CHART - ALL 5 DRUGS IN ONE PLACE

DRUG 1 - VANCOMYCIN (Empiric, Days 1-2)

DRUG 2 - PENICILLIN G (Aqueous Crystalline) (Definitive, Days 3-5+)